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Abstract  
 
Background: The spectrum of disorders of the brain is large, covering hundreds of disorders 
that are listed in either the mental or neurological disorder chapters of the established 
international diagnostic classification systems. These disorders have a high prevalence as well 
as short- and long-term impairments and disabilities. Therefore they are an emotional, 
financial and social burden to the patients, their families and their social network. In a 2005 
landmark study, we estimated for the first time the annual cost of 12 major groups of 
disorders of the brain in Europe and gave a conservative estimate of €386 billion for the year 
2004. This estimate was limited in scope and conservative due to the lack of sufficiently 
comprehensive epidemiological and/or economic data on several important diagnostic groups. 
We are now in a position to substantially improve and revise the 2004 estimates. In the 
present report we cover 19 major groups of disorders, 7 more than previously, of an increased 
range of age groups and more cost items. We therefore present much improved cost estimates. 
Our revised estimates also now include the new EU member states, and hence a population of 
514 million people. Aims: To estimate the number of persons with defined disorders of the 
brain in Europe in 2010, the total cost per person related to each disease in terms of direct and 
indirect costs, and an estimate of the total cost per disorder and country. Methods: The best 
available estimates of the prevalence and cost per person for 19 groups of disorders of the 
brain (covering well over 100 specific disorders) were identified via a systematic review of 
the published literature. Together with the twelve disorders included in 2004, the following 
range of mental and neurologic groups of disorders is covered: addictive disorders, affective 
disorders, anxiety disorders, brain tumor, childhood and adolescent disorders (developmental 
disorders), dementia, eating disorders, epilepsy, mental retardation, migraine, multiple 
sclerosis, neuromuscular disorders, Parkinson's disease, personality disorders, psychotic 
disorders, sleep disorders, somatoform disorders, stroke, and traumatic brain injury. 
Epidemiologic panels were charged to complete the literature review for each disorder in 
order to estimate the 12-month prevalence, and health economic panels were charged to 
estimate best cost-estimates. A cost model was developed to combine the epidemiologic and 
economic data and estimate the total cost of each disorder in each of 30 European countries 
(EU27+Iceland, Norway and Switzerland). The cost model was populated with national 
statistics from Eurostat to adjust all costs to 2010 values, converting all local currencies to 
Euro, imputing costs for countries where no data were available, and aggregating country 
estimates to purchasing power parity adjusted estimates for the total cost of disorders of the 
brain in Europe 2010. Results: The total cost of disorders of the brain was estimated at €798 
billion in 2010. Direct costs constitute the majority of costs (37% direct healthcare costs and 
23% direct non-medical costs) whereas the remaining 40% were indirect costs associated with 
patients' production losses. On average, the estimated cost per person with a disorder of the 
brain in Europe ranged between €285 for headache and €30,000 for neuromuscular disorders. 
The European per capita cost of disorders of the brain was €1550 on average but varied by 
country. The cost (in billion €PPP 2010) of the disorders of the brain included in this study 
was as follows: addiction: €65.7; anxiety disorders: €74.4; brain tumor: €5.2; child/adolescent 
disorders: €21.3; dementia: €105.2; eating disorders: €0.8; epilepsy: €13.8; headache: €43.5; 
mental retardation: €43.3; mood disorders: €113.4; multiple sclerosis: €14.6; neuromuscular 
disorders: €7.7; Parkinson's disease: €13.9; personality disorders: €27.3; psychotic disorders: 
€93.9; sleep disorders: €35.4; somatoform disorder: €21.2; stroke: €64.1; traumatic brain 
injury: €33.0. It should be noted that the revised estimate of those disorders included in the 
previous 2004 report constituted €477 billion, by and large confirming our previous study 
results after considering the inflation and population increase since 2004. Further, our results 
were consistent with administrative data on the health care expenditure in Europe, and 
comparable to previous studies on the cost of specific disorders in Europe. Our estimates were 
lower than comparable estimates from the US. Discussion: This study was based on the best 
currently available data in Europe and our model enabled extrapolation to countries where no 
data could be found. Still, the scarcity of data is an important source of uncertainty in our 
estimates and may imply over- or underestimations in some disorders and countries. Even 
though this review included many disorders, diagnoses, age groups and cost items that were 
omitted in 2004, there are still remaining disorders that could not be included due to 
limitations in the available data. We therefore consider our estimate of the total cost of the 
disorders of the brain in Europe to be conservative. In terms of the health economic burden 
outlined in this report, disorders of the brain likely constitute the number one economic 
challenge for European health care, now and in the future. Data presented in this report should 
be considered by all stakeholder groups, including policy makers, industry and patient 
advocacy groups, to reconsider the current science, research and public health agenda and 
define a coordinated plan of action of various levels to address the associated challenges. 
Recommendations: Political action is required in light of the present high cost of disorders of 
the brain. Funding of brain research must be increased; care for patients with brain disorders 
as well as teaching at medical schools and other health related educations must be 
quantitatively and qualitatively improved, including psychological treatments. The current 
move of the pharmaceutical industry away from brain related indications must be halted and 
reversed. Continued research into the cost of the many disorders not included in the present 
study is warranted. It is essential that not only the EU but also the national governments 
forcefully support these initiatives.   
 
 
 
1. Introduction  
 
1.1. EBC study on cost of disorders of the brain in 2005  
 
In 2005, the European Brain Council published the results of a comprehensive study 
estimating the cost of disorders of the brain in Europe in 2004 (Andlin-Sobocki et al., 2005; 
Wittchen and Jacobi, 2005), below called the EBC2005 study. The label “disorders of the 
brain” or in short “brain disorders” was chosen to acknowledge the communalities of mental 
and neurological disorders in terms of their substrate, the brain, as well as the increasingly 
broader evidence that both disciplines, despite different traditions, share many common 
methods and approaches. It should also be mentioned that various other terms that at least 
partly overlap exist, such as neuropsychiatric disorders, or MNS (mental, neurological and 
substance use disorders).  
 
In the EBC2005 study, the total cost in Europe, including the EU member states, Iceland, 
Norway and Switzerland, was estimated at €386 billion in 2004, distributed over 12 
diagnostic groups of important disorders of the brain affecting 127 million adult Europeans. 
The study was labeled a benchmark study because it was the first ever to attempt to combine 
the available epidemiologic and economic evidence of disorders of the brain in an effort to 
estimate their total cost within a common methodological framework. Moreover, it was 
instrumental in demonstrating the large societal cost associated with disorders of the brain and 
the importance of decisions on future strategies to alleviate their burden.  
 
The EBC2005 report had an enormous impact on various levels. Numerous highly listed 
disorder-specific and country-specific reports further exploring the economic consequences of 
disorders of the brain were important spin-offs of this first report. The 2005 report was 
presented to the European Commission and to European parliamentarians and has 
undoubtedly played a role in increasing the focus and shaping the political agenda on brain 
research and brain diseases at a European and national level. As a consequence, the number of 
studies exploring different aspects of the cost of disorders of the brain has steadily increased 
over time. In 2005, about 400 studies including the key words “cost” and “brain” were 
published (THOMSON REUTERS (ISI) 2010 http://portal.isiknowledge.com/). Over the next 
four years, this figure almost doubled, partly spurred by new initiatives coming out of the 
EBC2005 study (Andlin-Sobocki et al., 2005) (Fig. 1).  
 
1.2. Need for revision  
 
Our 2005 report could not cover many important disorders and cost items, mainly due to lack 
of data. During the past five years, the evidence base has grown and there are now 
possibilities for including previously omitted diagnoses and cost items. The larger evidence 
base also enables better precision in some of the estimates of the previously reviewed 
disorders of the brain. Further, Bulgaria and Romania are now part of the European Union and 
therefore are included in the present study.  
 
Since 2005, important steps have been taken to strengthen the research focusing on the 
disorders of the brain in Europe, most importantly the specific mention of mental health and 
brain research in the seventh framework program of research (FP7). However, there were also 
some more recent negative developments, such as the withdrawal of a number of major 
pharmaceutical companies from key areas of neuroscience research (Nutt and Goodwin, 
2011) and the move of industrial research away from Europe. While new initiatives, such as 
the Innovative Medicines Initiative by the EU, may give new opportunities, it is increasingly 
important that relevant information on the cost of disorders of the brain becomes available to 
decision makers. The present update and extension of the EBC2005 study is an attempt to fill 
this gap. It will hopefully serve to inform policy makers about the need for continuous focus 
on disorders of the brain in the forthcoming eighth framework program of research (FP8).  
 
1.3. Description of the study team  
 
The study was commissioned by the European Brain Council (EBC). It was designed and 
managed by a steering committee including professors Jes Olesen, Hans-Ulrich Wittchen and 
Bengt Jönsson in collaboration with lead health economists Anders Gustavsson and Mikael 
Svensson.  
 
The review of epidemiological data was conducted by panels of European experts (one panel 
for each disorder). The panel members for each disorder are listed in Table 1. A health 
economic expert panel was formed with the aim to validate the study design and assist in the 
interpretation of data. The panel was chaired by Prof Bengt Jönsson and included the 
following members: Dr. Gisela Kobelt, Dr. Linus Jönsson, Prof. Massimo Moscarelli and 
Prof. Martin Knapp.  
 
The coordination of the study, review of the economic data, analysis of data and drafting of 
reports was conducted by the company OptumInsight, led by Anders Gustavsson. The 
employees at OptumInsight contributing to this study included Korinna Karampampa, Mattias 
Ekman, Amir Musayev, Brenda Gannon and Christina Ljungcrantz.  
 
1.4. Study objective  
 
The objective of this study was to estimate:  
 
1. the number of persons with defined disorders of the brain in Europe in 2010  
2. the total cost per person related to each disease by specifying direct and indirect costs  
3. to estimate the total cost per disorder and country.  
 
More generally, the aim was to provide a revised, improved, up-to-date estimate of the cost of 
disorders of the brain in all of Europe, incorporating relevant cost items, diagnoses and age 
groups that were not included in the EBC2005 study due to limitations in the available data.  
 
 
2. Methods  
 
2.1. Study scope  
 
2.1.1. Disorders of the brain  
The methods and design of this study have already been presented largely in a separate 
publication mainly focusing on epidemiological data (Wittchen et al., 2011). The list of all 
diagnostic groups (ICD-10 codes) included in the study is presented in Table 2.  
 
2.1.2. Geographical scope  
All 27members of the European Union (EU27) and Iceland, Norway and Switzerland are 
included in this study. These 30 countries are two more than in the EBC2005 study (Andlin-
Sobocki et al., 2005) in which Bulgaria and Romania were not included (they joined the EU 
on January 1st 2007). These countries overall comprise a total of 514 million people (Table 
3).  
 
2.2. Methodological approach  
 
The aim of a cost of illness study is to assess the cost of a defined disease. There are several 
approaches to this; the chosen approach depends on the specific purpose of the study and the 
data available.  
 
2.2.1. Societal perspective  
This study has a societal perspective which implies that we have considered the costs of all 
resources used or lost due to the disease, irrespective of who the payer is. This perspective is 
the most relevant for decision makers whose main interest is the welfare of the society as a 
whole. It is also the relevant perspective for judging if all costs are included but it is important 
to include each cost item only once in order to avoid double counting. Other perspectives, 
such as that of a health care provider, may only consider the costs of a certain hospital in 
order to optimize the health care delivery of that hospital within a given budget. Costs are 
presented in three main categories:  
 
a) direct health care costs (i.e. all goods and services related to the prevention, diagnosis and 
treatment of a disorder; e.g. physician visits, hospitalizations and pharmaceuticals),  
b) direct non-medical costs (i.e. other goods and services related to the disorder; e.g. social 
services, special accommodation and informal care), and  
c) indirect costs (i.e. lost production due to work absence or early retirement).  
 
Informal care is sometimes considered to be an indirect cost but we have chosen to include it 
under direct non-medical costs because it replaces formal services that would have fallen into 
this category.  
We have excluded a number of cost items from our estimates due to the lack of data or lack of 
consistent methods on how to value and report these costs. These include indirect costs due to 
premature mortality, intangible costs (i.e. the monetary value of suffering from a disorder), 
and costs of crime caused by e.g. addiction. We have also excluded costs related to research 
because they are not considered to be caused by the disorder per se, but rather as an 
investment aimed at reducing the costs in the future. Moreover, to a large extent, research 
costs will likely be reflected in the prices of potential treatment interventions coming out of 
this research.  
 
2.2.2. Prevalence-based approach  
The total cost of a disorder can be calculated by combining epidemiologic (number of 
patients) and economic data (cost per patient), and there are two main approaches for this. The 
prevalence-based approach multiplies the total number of persons affected by a disorder in a 
given year (this means 12-month period) with their mean cost in the same year. The 
alternative, incidence-based approach, multiplies the total number of new onset persons with a 
disease in a given year with the life-time cost of these new persons. If all underlying 
conditions (e.g. incidence rate, mortality, population size, treatment practices and prices) 
would be stable over time, the prevalence-based and incidence- based approaches would give 
the same result. In practice, the two methods are based on different data and assumptions and 
thus might give different results and interpretations (Hodgson and Meiners, 1982).  
We chose the prevalence-based approach for several reasons. First, it fits the specific study 
objective to estimate the cost attributed to the disease in a given year (2010) rather than 
estimating the life-time cost of patients first diagnosed in this year. Second, for most disorders 
of the brain included in this study, annual prevalence data is available whereas incidence 
studies are rare, due to the inherent methodological complexities and higher costs involved in 
doing such studies. Third, it enables the comparison with the EBC2005 study results as the 
prevalence-based approach was used in that study as well (Andlin-Sobocki et al., 2005). 
Fourth, most available economic data provide estimates of the costs of patients over a short 
period of time rather than life-time costs. Moreover, most brain disorders have an insidious 
onset followed by worsening and often chronic symptoms, and for such conditions the most 
reliable epidemiologic data constitute prevalence estimates derived from community-based 
samples. However, there are exceptions (e.g. stroke and traumatic brain injury) which differ 
from the other disorders in that their onset is sudden and followed by an intensive period of 
care followed by rehabilitation and potentially cure. For such disorders, incidence rates are 
mainly available and the cost of patients during a period following disease onset. In the 
EBC2005 study only the cost of the first year following incident cases of stroke and traumatic 
brain injury was reported (Andlin- Sobocki et al., 2005). In this study, we have also included 
estimates on the cost of patients suffering from the long term consequences of these two 
diseases, as an approximation of the costs for patients with a previous onset of disease.  
 
2.2.3. Bottom–up cost-of-illness  
In the so called bottom–up cost-of-illness studies, cost data are collected by identifying 
persons with a certain disease and assessing their individual cost (e.g. by interview, 
questionnaire or review of their medical records). The mean cost per person is then multiplied 
by the number of persons to get an estimate of the total cost.  
The alternative top–down method uses national or regional statistics on the total costs of a 
group of disorders/in a country/etc. to tease out the cost of a certain disease. Bottom–up 
studies benefit from often being more complete in terms of what resources are available, 
andmore accurate in terms of the selection of persons because the information on diagnoses 
are usually sparse in the available national statistics. The disadvantage of bottom–up studies is 
a higher risk of double-counting costs as a certain person may suffer from several disorders, 
and it is generally difficult to determine which one that is actually causing the costs. This 
problemis handled in most cost-of-illness studies by trying to separate and only count the 
specific costs due to the disorder, rather than the total cost of a patient with the disorder. This 
can be done by asking the person to report only the resources used due to the disorder of 
interest, and by including only the treatments that are specific for the disorder. Another 
approach is to compare the total cost for patients with the disorder with a matched control 
group without the disorder, and consider the difference in cost to be caused by the disorder of 
interest (Hodgson and Meiners, 1982).  
We aimed to identify patient level data on annual direct and indirect costs for each disorder; 
however, in the case that no other data was available, we made use of estimates from top–
down studies. Such estimates, often based on main diagnoses for hospitalization or other 
events, were also used for the validation of the bottom–up estimates.  
 
2.2.4. Selection of patient samples  
Many cost studies are based on patient convenience samples recruited from a clinic, health 
care center or for a specific study with defined inclusion and exclusion criteria. Such samples 
may not be representative of the persons with that disorder in the general population. For 
instance, patients seen at a specialist treatment center might be considered to be typically 
more severe than patients in the general patient population or in primary care. By contrast, 
epidemiologic studies are typically designed to be representative to the general population or 
fractions thereof by recruiting persons according to random sampling plans based on registers 
of the total population in a specific region or the whole country (so-called community 
surveys).  
Such differences should be considered when the cost per patient and the prevalence data are 
multiplied to give an estimate of the total cost of the disorder. Proper considerations of such 
differences can be partially accounted for by separating the treated and untreated patient 
populations and use different cost estimates for the two, or use separate cost per patient and 
prevalence estimates for patients at different ages or severity of disease. Such methods were 
used in this study to avoid inflated estimates and to improve transparency and validity, but the 
specific disaggregation was determined separately for each disorder depending on its 
characteristics and the available data.  
Another problem inherent in our approach is that prevalence data from community study 
rarely covers the whole age range. Frequently prevalence data from the same study are only 
available for children and adolescents or only adults and/or the elderly. Rarely is the full 
spectrum of all ages covered within one single study design, mostly due to the different 
assessment needs. Thus it remains sometimes questionable to what age range the respective 
epidemiological and cost data apply. In case of doubt, one should choose a conservative 
approach only applying cost data to those prevalence data, for which the valid age range has 
been established.  
 
2.2.5. Prevalence data search  
The epidemiologic data in this report was retrieved from published literature, obtained from a 
disorder specific literature review performed by the epidemiologic panels. The review sought 
to identify the 12-month prevalence data by disorder and country. For many disorders, 
country specific data was either not available or did not provide sufficient detail. In these 
cases we extrapolated the available evidence for countries with data to countries without data. 
In order to validate this procedure, country-specific surveys were additionally performed, 
reported elsewhere (Wittchen et al., 2011). Where applicable, the prevalence data was 
stratified by age, gender and disease severity. See disorder specific information below for 
details.  
 
2.2.6. Cost data search  
A search for relevant cost literature was carried out in the electronic bibliographic database 
PubMed (MEDLINE). From this search we expect to have identified all relevant published 
original research articles from all relevant peer-reviewed journals. The search strings were 
combinations of search terms for each specific disorder, search terms related to cost studies, 
and a list of relevant countries (see appendix for detailed search strings). The title and 
abstracts of all hits with an English abstract were reviewed in order to exclude that articles 
that did not provide relevant information. The articles that could potentially include useful 
information were reviewed as full texts. The search was conducted between January and June 
2010.  
The inclusion criteria were as follows:  
• The article included data on costs or resource use.  
• The data was based on a sample of patients with the relevant diagnosis.  
• The article included data from any of 30 European countries (EU27, Iceland, Norway and 
Switzerland).  
• The article was written in English, French, German, Italian or Spanish.  
• The article was published on January 1st 2004 or later.  
• The study had sound and robust methodology for patient selection, data collection, 
instrumentation, statistical analysis and reporting of results.  
Articles reporting the cost of patients in clinical trials were excluded, because these are 
generally not considered to be representative of the patient population in clinical practice.  
Review articles including data on cost-of-illness studies were included and their reference 
lists were searched for relevant original research articles. Cost-effectiveness studies were 
searched for relevant input data but were excluded if they were only based on data from 
clinical trials or assumptions. The reference lists of the identified studies were reviewed for 
further inclusion of relevant original research articles. Finally, the studies identified in the 
previous EBC study (Andlin-Sobocki et al., 2005) were included.  
Country specific data for each disorder was used as input in the European cost of illness 
(COI) model. When there were several studies for one disorder and country, the un-weighted 
mean of several estimates was calculated. In some cases where one study was preferred to 
others, a rationale was provided for only considering the preferred study in the model 
calculations. 2.3. Description of the European COI model The total cost of each disorder for 
all European countries was estimated by multiplying the cost and prevalence estimates 
identified in the literature review. However, in many countries there were not sufficient data 
available. Moreover, the available cost estimates were from various years and were reported 
in various currencies. We therefore developed a European COI model to enable estimation of 
the total cost of all brain disorders in 2010, in each country and with a comparable currency. 
The following sections describe this model.  
 
2.3.1. Adjusting cost estimates to 2010 values  
Because cost studies were conducted at varying points in time, their cost estimates were also 
reported for different years. The cost of a certain disorder in 2010 may be assumed to be equal 
to the estimated cost in a previous year, adjusted for the inflation. All cost estimates were 
therefore multiplied by the inflation rate in the relevant country. We selected the Consumer 
Price Index (CPI) for a standard basket of goods [prc_hicp_aind] irrespective of what 
resources were included in the cost estimate (Eurostat 2010http://appsso.eurostat. 
ec.europa.eu/nui/show.do?dataset=prc_hicp_aind&lang=en). There are alternative indices 
available (e.g. CPI for health care goods) but the general CPI index was preferred because it is 
the most established of the available indices and should therefore be most coherent across 
different countries. Further, the difference between the general and the health care goods 
indices was small (the two suggested indices differed less than 1.2% over the last 5 years in 
EU27).  
 
2.3.2. Conversion of national currencies to Euro  
In order to compare and aggregate costs across countries, costs need to be converted into a 
common currency. Nominal exchange rates can be used to convert all currencies into nominal 
Euro, and the aggregate of all countries will then indicate the sum of the costs of all goods and 
services in Europe (valued at their local prices). However, because price levels vary within 
Europe, the comparison of nominal costs across countries does not accurately reflect their real 
value from a European perspective. For instance, it may be that two countries have the same 
resource utilization, but because of different price levels they end up with different costs. 
Instead, conversion to a common currency using real exchange rates results in comparable 
costs valued at a European price level (real Euro). The limitation of such estimates is that they 
do not reflect the actual spending in each individual country.  
The estimates presented in this report were converted to real Euro, using nominal exchange 
rates from the European central bank (ECB) (European Central Bank 2010. 
http://sdw.ecb.europa.eu/browse.do?node=2018779) adjusted for comparative price levels 
(CPL) for 2009 from Eurostat [prc_ppp_ind] (Eurostat 2010. 
http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=prc_ppp_ ind&lang=en). CPL is 
defined as the ratios of purchasing power parities to exchange rates. The selected CPLs were 
based on the total consumption in each country (GDP), i.e. not limited to price differences in 
health care goods. The data reported from Eurostat are equal to the corresponding indices 
from OECD (OECD statistics 2010. http://stats.oecd.org/).  
 
2.3.3. Extrapolation across countries to fill data gaps  
Extrapolation from one country where data is available to another where no data is available 
gives an indication of the burden of a disorder in the latter country, and enables estimation of 
the overall burden of all disorders in Europe. The European COI model performed such 
extrapolation for both the prevalence and cost of each disorder.  
The median prevalence ratio, calculated from all countries with available estimates, was 
assumed for countries without any country specific data. The median was preferred to its 
alternative (i.e. the arithmetic mean) because it is less sensitive to influential outliers (e.g. 
relatively high estimates in single countries or studies which would otherwise have 
unreasonable impact on the average).  
The median was considered also for cost extrapolation, but adjusted for income, health care 
expenditure, and wage level differences across countries. That is, the European median was 
multiplied by an index of the relative income, expenditure or wage level in each individual 
country, depending on the cost type. The national health care expenditure was considered for 
direct health care costs, the gross domestic product (GDP) for direct nonmedical costs, and 
the wage level for indirect costs.  
These indices were available from Eurostat but the most recent were from 2008 and they were 
missing for some countries. The health care expenditure data from Eurostat [hlth_sha1h] 
(Eurostat 2010. 
http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_sha1h&lang=en) had to be 
complemented by data from OECD (total expenditure on health, % of gross domestic product) 
(OECD statistics 2011. http://stats.oecd.org/index.aspx?DataSetCode = HEALTH_STAT) 
combined with data on GDP from Eurostat [nama_gdp_c] (Eurostat 2010. 
http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=nama_gdp_c&lang=en). For 
countries where no data for 2008 were available, an older estimate was inflated by a 
comparative price index for health care expenditure [prc_hicp_aind] (Eurostat 2010. 
http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=prc_hicp_aind&lang=en). GDP data 
were available from Eurostat for 2009 for most countries, but we used 2008 figures as they 
were complete [nama_gdp_c] (Eurostat 2010. 
http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=nama_gdp_c&lang=en). Data on 
wage levels were available by combining several Eurostat sources [earn_gr_nace, 
earn_gr_nace2; earn_gr-isco; tps000174]; (Eurostat 2010. 
http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=en&pco
de=tps00174) (Eurostat 2010. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset = earn_ 
gr_nace&lang=en; Eurostat 2010. 
http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=earn_gr_nace2&lang=en; Eurostat 
2010. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=earn_gr_isco&lang=en), and 
for countries where no data for 2008 were available an older estimate was inflated by a 
Eurostat labour cost index [lc_lci_r1_a] (Eurostat 2010. 
http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=lc_lci_r1_a&lang=en).  
 
2.3.4. Aggregation of data  
The prevalence ratios were multiplied by the number of people in each respective country. 
Data for 2010 were available on the population size by 1 year age spans for each country from 
Eurostat [demo_pjan] (Eurostat 
2010http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_pjan&lang=en), which 
enabled calculating the number of persons with each disorder in relevant age groups. The 
number of persons with each disorder was then multiplied by the country-specific estimates of 
the cost per patient.  
For some disorders, the direct costs were multiplied by a “treatment rate” to adjust for 
disorders where the available cost estimates only referred to a subset of the total population 
with the disorder (see disorder specific information for details).  
Further, indirect costs were only applied to the working population (i.e. age between 18 and 
65), unless the indirect cost estimates were actually presented as an average of the total 
population of all ages. For some disorders, the identified cost studies presented the mean 
indirect cost of the whole population, including also the zero estimates of patients not working 
because of other causes than the disorder (e.g. being underage or retired). This was the case 
for brain tumor, traumatic brain injury, alcohol addiction and neuromuscular disorders. For 
epilepsy, the cost studies presented estimates for a mix of age ranges for different countries; 
some for all ages, others for 18+ or 18–65. We selected the age range 0–65 as a compromise 
because considering all ages (or 18–65) would overestimate (or underestimate) the indirect 
cost.  
 
 
2.4. Methods for validation  
 
The results of this study were validated by comparison with the EBC2005 study (Andlin-
Sobocki et al., 2005). Some of the differences are explained by the inclusion of certain 
disorders and costs in this revision that were omitted in the EBC2005 study. Other differences 
can be explained by new prevalence or cost estimates, or by new assumptions that have been 
considered appropriate this time. Details on all these aspects are provided in the Results 
section.  
 
The estimates of the European costmodel were also compared with external data from 
administrative databases, other European reviews of certain disorders and studies from the 
United States. An unstructured review of such sources and studies was conducted in PubMed, 
complemented by studies that were known to the study team.  
 
 
3. Results  
 
3.1. Previously (review 2005) reviewed disorders of the brain  
 
3.1.1. Number of persons  
The total number of persons with any of the 12 previously reviewed group of disorders of the 
brain was estimated at 179 million (Table 4). In the EBC2005 study this estimate was lower 
(127 million) (Andlin-Sobocki et al., 2005). About 10.4% of this difference is explained by 
the increase in the underlying population, i.e. the population increase in each country from 
2004 to 2010 and the addition of Bulgaria and Romania which were not included in the 
EBC2005 study. The remaining difference is mostly explained by coverage of a broader age 
range, like including children or the elderly, allowed for by new data since 2004, enabling 
more precise estimates for some disorders.  
New studies have also suggested the need for mostly minor changes in prevalence rates for 
some disorders. The overall higher number of addiction resulted from a higher estimate of the 
prevalence of alcohol dependence in eastern EU states leading to a subtle increase from 2.4 to 
3.4%. This increase was partially offset by the exclusion of cannabis dependence (estimated 
prevalence of 0.4%). An estimate of the cost of cannabis dependence was included in the 
previous EBC study (Andlin-Sobocki and Rehm, 2005), but based on questionable data, and 
reliable evidence on the cost of this disorder in Europe is still lacking. Persons with cannabis 
dependence are therefore not included in the cost estimates presented here. The higher 
prevalence of brain tumors was explained by the inclusion of benign tumors, contributing 
with an increase in the overall prevalence by 60%. The latest review of the literature on the 
prevalence of migraine showed a mean of 15%, compared to 13.6% that was considered for 
the EBC2005 study (Berg and Stovner, 2005). In multiple sclerosis, a change in the diagnostic 
criteria has resulted in earlier detection of the disease and consequently a higher prevalence.  
For the EBC2005 study (Andlin-Sobocki and Wittchen, 2005b), only persons between the age 
of 18 and 65 were considered for anxiety disorders. In this report we felt confident to widen 
the age span covered. However, this required a number of adjustments with regard to the 
prevalence estimates, which had an impact on the estimated number of persons affected.  
The overall 12-month prevalence estimates were adjusted for dementia and Parkinson's 
disease. We extended the lower age range for dementia to age 60, compared to 65 that was 
used in the 2005 report, which led to an increase in the number of persons included. For 
Parkinson's disease, we considered the prevalence estimates in two age groups (40-69 years - 
prevalence of 0.1% on average, and persons above 70 years old - prevalence 1.5%), compared 
to the EBC2005 study (Lindgren et al., 2005) where only the prevalence of the disorder in 
persons above 65 years of age was taken into account. This however, did not result in a 
significant change in the estimated number of persons with the disease, likely because the 
prevalence rates adjusted for age resulted in a lower prevalence overall.  
Age group adjustments were also made for major depression, anxiety disorders (see below for 
GAD), psychotic disorders and traumatic brain injury, whenever there was evidence of 
significantly different prevalence rates by age group, thatwould be associated with overall 
inadequate estimations of the number of persons affected. For alcohol addiction, all persons 
above 15 years of age were considered with prevalence estimates adjusted for age and 
geographical region. For opioid dependence, the age range 15–65 was considered with an 
estimated prevalence rate between 0.4 and 0.1%, decreasing with age. For generalized anxiety 
disorder (GAD), two age groups were considered; 14–65 with a prevalence of 1.7% and 66+ 
with a prevalence of 3.4%.  
 
3.1.2. Cost per person  
On average, the overall cost per person with any of the 12 previously reviewed disorders of 
the brain decreased from €3040 in 2004 to €2670 in 2010 (Table 4).  
The decrease in the overall cost per person was seen despite an underlying inflation of 14.5% 
(average for EU27, weighted by the total consumption in each country). The primary 
explanation was that the last six years have produced many new studies and in countries 
where there were no prior evidence. In many cases these studies have shown lower costs than 
what our estimates showed in the EBC2005 study (Andlin-Sobocki et al., 2005), but in others 
the new studies points to higher costs.  
A decrease in the inflation adjusted estimates of the cost per person was seen in seven 
disorders: addiction, brain tumor, epilepsy, migraine, mood disorders, psychotic disorders and 
traumatic brain injury. In alcohol addiction, four new studies all show lower costs than the 
two studies used in the previous EBC study (Andlin-Sobocki and Rehm, 2005). In opioid 
dependence, three new studies show similar costs in the UK but lower estimates for France 
and Spain which results in a lower European average than in the one estimated from the 
EBC2005 study (Andlin-Sobocki et al., 2005). In brain tumor, the decrease was due to the 
exclusion of indirect costs due to mortality (which were included in the EBC2005 study) 
accounting for 73% of the indirect costs. The direct cost actually increased due to new 
estimates available for high grade gliomas which are relatively more costly than other tumors. 
This increase also mirrors increased costs for new treatments which have become available in 
the recent years. In epilepsy, the recent evidence shows more variation in the costs across 
European countries, with low cost estimates in Italy and France which results in a lower 
average overall.  
For migraines, the decrease in the cost per person was mainly explained by the exclusion of 
the indirect cost associated with presenteeism (i.e. productivity losses due to reduced 
efficiency of persons who are not sufficiently ill to be absent from work). This cost is an 
important part of the economic burden of migraines, and an estimate was included in the 
EBC2005 study (Berg and Stovner, 2005) but the method for estimating this cost is not 
considered sufficiently established to be included in this revision. In mood disorders, the cost 
per person of major depression decreased due to lower indirect cost estimates from studies in 
Spain and the Netherlands, whereas estimates for bipolar depression remained unchanged. 
Also, the mean cost per person with a mood disorder decreased as a result of the inclusion of a 
wider age range for major depression causing an increase in the proportion of these persons 
with lower costs relative to those with bipolar disorder. In psychotic disorders, a new 
prospective study has shown lower costs per person than previously reported (Andlin-Sobocki 
and Rossler, 2005). For traumatic brain injury, the estimate presented in the EBC2005 study 
was based on a single estimate for patients admitted to hospital irrespective of severity (Berg 
et al., 2005). The revised estimate is based on separate estimates for each severity (mild, 
moderate and severe traumatic brain injury). This resulted in a slightly lower cost per person 
on average, probably because the more severe cases were overrepresented in previous 
estimates.  
The inflation adjusted estimates of cost per person increased for dementia. Recent cost studies 
have shown higher informal care costs in southern Europe (France and Spain) and also higher 
costs associated with special accommodation and community services in northern Europe 
(Sweden and the UK).  
The cost per person remained on the same level (absolute difference less than 6%) for the 
remaining four disorders: anxiety disorders, multiple sclerosis, Parkinson's disease and stroke.  
 
3.1.3. Total costs  
The total cost of the 12 previously reviewed disorders of the brain increased from €386 billion 
in the EBC2005 study to €477 billion in 2010 (Table 4). This 23% increase should be 
compared with an expected 25% increase if simply inflating the cost estimated from 2004 to 
2010 values and population size.  
Total costs, adjusted for the population increase and inflation, were higher for four disorders 
(anxiety disorders, dementia, multiple sclerosis and traumatic brain injury), lower for six 
disorders (addiction, brain tumor, epilepsy, migraine, mood disorders and psychotic disorders) 
and remained the same (difference smaller than 4%) for Parkinson's disease and Stroke. The 
changes could be attributed to the differences in the number of persons and costs per person 
compared to the estimates in the EBC2005 study, as described above.  
 
3.1.4. Extension to estimates of previously reviewed disorders  
The estimates described above excluded some important cost items and diagnoses, which 
were also not included in our previous study. Table 5 shows extensions to the 12 previously 
reviewed disorders of the brain, including diagnoses and costs that were omitted in the 
EBC2005 study (Andlin-Sobocki et al., 2005) due to lack of data.  
With regard to anxiety disorders, we now included Post Traumatic Stress Disorder (PTSD) 
which resulted in an additional 7.7 million persons and 8.4 billion Euro in costs.  
New data from the Eurolight study (Linde et al., 2011) enabled addition of non-migrainous 
headaches (tension type headache, medication overuse headache, and other headaches) to the 
cost of migraine. Tension type headache is a very common disorder, albeit not very costly, 
affecting a quarter of the European population. The non-migrainous headaches therefore add 
103 million persons and €25 billion in total costs. Further, the numbers of persons suffering 
from the long term consequences of a previous stroke or traumatic brain injury were estimated 
at 7 and 2.5 million, and their costs were estimated at €37 and €23 billion, respectively. 
Finally the indirect costs of psychotic disorders and traumatic brain injury were not included 
in the EBC2005 study (Andlin-Sobocki et al., 2005), but were now estimated at €70 billion. 
Altogether, the 12 previously studied disorders now affect 300 million persons (Table 6) and 
their total cost is €640 billion per year in Europe (Table 8).  
Tables 6–8 present the country specific estimates of number of persons, cost per person and 
total costs for the 12 previously reviewed disorders including extensions.  
 
3.2. New disorders of the brain  
 
3.2.1. Description of included disorders  
In addition to the 12 previously studied disorders, seven additional disorder groups were 
included in the present 2010 analysis as listed in Table 9. The methodological approach for 
these disorders was identical to that of the previously reviewed disorders, with one difference 
being that no restriction was set regarding the year of publication (i.e. also publications before 
2004 were included in the literature search).  
For most of the additional disorder groups, it was only possible to include a subset of all 
conditions as listed in ICD-10. For inclusion, relevant and reliable prevalence and cost data is 
necessary; generally, it was the lack of cost data that was the reason for excluding conditions. 
Table 9 summarizes the included conditions in each disorder group.  
Child and adolescent disorders include autism spectrum disorders (ASD), attention deficit 
hyperactivity disorder (ADHD), and conduct disorder (CD). Eating disorders includes 
Anorexia Nervosa (AN) and Bulimia Nervosa (BN). Mental retardation is also sometimes 
denoted intellectual disability. For personality disorders (PD) two conditions from the PD 
cluster B were included: borderline PD and antisocial PD. For sleep disorders (SD), it was 
possible to include narcolepsy, hypersomnia, insomnia and sleep apnea.  
Neuromuscular disorders cover a wide range of different conditions, but lack of relevant cost 
data made it impossible to include a vast range of significant conditions. In the end we 
grouped the included conditions as follows: (1) muscular dystrophies and other genetic 
myopathies (Duchenne, Becker, Facioscapulohumeral, Limb Girdle, Emery–Dreifuss, 
Oculopharyngeal MD, congenital MDs, congenital myopathies, distal and myofibrillar 
myopathies and myotonic dystrophies), (2) acquired neuropathies (chronic inflammatory 
demyelinating polyradiculoneuroapthy, multifocal motor neuropathy, paraproteinemic 
polyneuropathies, Guillain– Barré) and amyotrophic lateral sclerosis (ALS), (Nutt and 
Goodwin, 2011) autoimmune disorders of muscle and of the neuromuscular junction (only 
possible to include Myasthenia Gravis). Hence, important conditions such as hereditary 
neuropathies (e.g. Charcot–Marie Tooth disease), spinal muscular atrophies, inflammatory 
myopathies (dermatomyositis, polymyositis, and inclusion body myositis, glycogen storage 
diseases, mitochondrial cytopathies) and several other conditions are lacking in the cost 
analysis.  
For somatoform disorder, the majority of studies included pain disorder. Studies differed 
regarding the strategy and applied criteria for ‘Undifferentiated Somatoform Disorder’ (i.e. 
conditions of clinical relevance that do not fulfill the rather strict criteria for somatization 
disorder or the criteria for any specific other somatoform disorder).Other diagnoses that fall 
into the category of somatoform disorders were not included due to lack of reliable prevalence 
and cost data (body dysmorphic disorder, hypochondria, dissociative disorder NOS, 
conversion disorder).  
 
3.2.2. Number of persons  
The total number of persons with any of the seven additional disorders of the brain was 
estimated at 81 million (Table 10), which adds 45% to the number of persons with any of the 
12 previously reviewed disorders. It was estimated that there are approximately 45 million 
persons with sleep disorders, 20 million persons with somatoform disorder, and 6 million with 
child and adolescents disorders, whereas personality and Intellectual Developmental Disorder 
were both estimated to affect slightly more than 4 million persons. Eating disorders was 
estimated to affect 1.5 million persons, and the number of persons with neuromuscular 
disorders was estimated at 0.26 million. However, as mentioned in the previous section, there 
were a vast range of neuromuscular conditions not included in this estimation.  
 
3.2.3. Cost per person  
The average cost per case for each disorder group is shown in Table 11. The European crude 
average varies between €559 for eating disorders up to €30,052 for neuromuscular disorders.  
The cost per person for all seven disorders is based on direct and indirect costs with the 
exception of mental retardation that only contains direct costs and it is therefore not directly 
comparable to the other disorder groups.  
The highest estimated cost per person is seen for neuromuscular disorders (NMDs) at nearly 
€30,000 per person and year (European average). The high cost is to a large extent explained 
by direct health care costs, considering that many NMDs are treatable but with (currently) 
expensive treatment options. Even though the estimate for mental retardation does not contain 
indirect costs, it has the second highest cost per person. If indirect costs would have been 
included, cost per person would be substantially higher considering that we know that for 
persons with mental retardation, employment is very low (Martinez-Leal et al., 2011).  
For child and adolescent disorders, where the cost per case is €3600 based on a higher cost for 
autism spectrum disorders and slightly lower for attention deficit hyperactivity disorder and 
conduct disorder, a large share of costs is direct non-medical costs. This is primarily due to 
increased costs for education and social services for children and adolescents with autism 
spectrum disorders. But there are also significant informal care costs due to the fact that 
parents and caretakers experience reduced productivity and employment in order to care for 
the children and adolescents.  
For the disorder groups with the lowest cost per person (sleep disorders and eating disorders), 
the largest share of costs are direct costs for eating disorders and indirect costs for sleep 
disorders. The former is partly explained by the fact that prevalence of eating disorders is 
higher among adolescents, where lost productivity due to non-employment is less relevant. 
However, impact on schooling may affect productivity and income later in life.  
 
3.2.4. Total costs  
Table 12 summarizes the total cost estimation for the seven new disorder groups; in power 
purchase adjusted billion Euros. The total cost for the seven new disorder of the brain was 
estimated at €157 billion.  
The highest cost is seen for mental retardation at around €43 billion, despite the omission of 
indirect costs. Sleep disorders are estimated at a cost around €35 billion (excluding the 
indirect cost of insomnia). The explanation for the relatively high cost of sleep disorders is 
found in the high number of persons, especially for insomnia, whereas cost per person is not 
as high (with the exception of narcolepsy).  
Total cost for personality disorders is approx. €27 billion in Europe in 2010 whereas cost for 
child and adolescent disorders is approx. €21 billion. For the latter it should be noted that this 
only includes children and adolescents, and hence costs for disorders such as autism spectrum, 
for example, among adults are not included in the cost estimate.  
Total cost for neuromuscular disorders is approximately €8 billion, but as noted above, this 
only includes a subset of the vast range of neuromuscular conditions. Most neuromuscular 
disorders are very rare, but as was seen in the previous section, the cost per person is very 
high. Finally, the total cost of eating disorders is the lowest among the seven new disorders of 
the brain at approx. €800 million, explained both by a, in comparison, relatively smaller 
number of persons and relatively lower cost per person.  
The total cost of somatoform disorders is estimated at €21 billion. This is a very conservative 
estimate for this disorder which constitutes a group of persons that are difficult to manage 
consuming an exceedingly high degree of health care resources (Salawu et al., 2009) without 
an established medical need for such services and resources.  
Finally, as seen in Table 12, total cost estimates vary significantly across European countries, 
naturally explained by the significant variance in number of persons due to the different 
population sizes. Further, costs are higher in countries with higher income, which generally 
have higher health care expenditure and with higher wages also follow higher indirect cost for 
each day of absence. The highest cost for all seven disorders together is found in Germany 
(€31 billion), followed by the UK (€24 billion) and France (€21 billion).  
 
 
 
 
3.3. An overview of the cost of disorders of the brain  
 
3.3.1. Cost per person  
The cost per person with a brain disorder is highly variable (Fig. 2). A person with a 
neuromuscular disorder is estimated to cost €30,000 for any given year. At the other end, a 
person with headache only incurs €285 per year on average.  
 
3.3.2. Aggregated costs  
Simply aggregating the number of persons and costs of all disorders of the brain is hazardous, 
because there is a risk of double counting. Many persons might have multiple disorders and 
are included potentially in the prevalence estimates for specific disorders more than once. It is 
difficult to attribute the resource use and indirect costs to a specific disorder if the person 
suffers from many disorders. This may lead to the same cost being counted for and included 
in different disorders. To the extent possible, we have corrected for double counting in the 
cost estimates by considering the excess cost for each disorder (i.e. the additional cost that a 
person with the disorder causes, irrespective of whether they have any other disorders or not). 
Thereby, we have not attempted to correct for double counting in the number of persons with 
the disorder, but instead in what additional cost they incur. Still, the available evidence is 
limited and we have not considered all overlap between the 19 disorders and the individual 
diagnoses within each of these disorders that are included in this study.  
With this caveat in mind, we report the total number of persons and costs for all disorders of 
the brain in Table 13. The total number of persons is estimated at 380 million. Again, this 
does not mean that there are so many persons with a disorder of the brain, since many of them 
have two or more. The aggregated cost brings €798 billion for the whole of Europe in 2010. 
The most costly disorders are mood disorders which incur both high direct healthcare costs 
but even higher indirect costs because persons are not able to work, and dementia because of 
very high direct non-medical costs (Fig. 3).  
Mental disorders in a stricter sense are mood disorders, psychotic disorders, anxiety disorders, 
addictive disorders, mental retardation, personality disorders, child and adolescent disorders, 
somatoform disorders and eating disorders. Together the estimated cost for these mental 
disorders is €461 billion.  
Leaving aside the fact that sleep disorders and dementia are also listed in the ICD-10 under 
mental disorders, as well as stroke under cardiovascular conditions, neurological disorders can 
be defined as dementia, stroke, headache, sleep disorders, traumatic brain injury, multiple 
sclerosis, epilepsy, Parkinson's disease, brain tumor and neuromuscular disorders. Together 
the estimated cost for neurological disorders is €336 billion. Out of all disorders of the brain, 
mental disorders account for 58% and neurological disorders for 42%. However, the 
separation of brain disorders into those categories is to some extent arbitrary and several of 
the categories are managed by both specialties.  
 
3.3.3. Country specific estimates  
The total cost for all disorders of the brain in individual countries ranged between 437 million 
in Malta and 153 billion in Germany (Table 14). Dividing these figures by the population size 
in each country provides the per capita cost shown in Fig. 4. The mean cost per capita in 
Europe was estimated at €1550. The country specific estimates should be interpreted with 
caution as they are a result of model estimations from the European cost model. The available 
data are highly limited or absent in many countries. In absence of local data, the estimates are 
entirely based on extrapolations from the evidence for other countries, adjusting for 
differences in income, wage levels and health care expenses. Regardless, methodological 
limitations leading to discrepancies when comparing across countries cannot be avoided. For 
example in the UK, the wage level is considerably higher compared to other European 
countries (about 70% higher compared to the un-weighted mean in Europe, whereas the 
health care expenditure and GDP are only about 11–12% higher). This may explain the 
relatively high proportion of indirect costs in the UK compared to other countries. In addition, 
there may still be differences in care patterns across countries that we did not take into 
consideration in the model.  
 
3.3.3.1. Distribution of costs. Overall, the majority of the estimated costs of disorders of the 
brain were direct costs (60%) while indirect costs constituted the remaining 40% (Fig. 5). 
Indirect costs constitute a higher percentage of total costs in mental disorders, compared to 
neurological disorders.  
Further, there was a large variation across the disorders (Fig. 6). Persons with eating disorders 
had the highest proportion of direct healthcare costs (72%), whereas they only constituted 
12% of the total in child/adolescent or personality disorders. The direct nonmedical cost 
constituted the highest proportion in child/adolescent disorders (88%) and dementia (84%). 
Indirect costs made up the bulk of the costs in personality disorders (78%) and headache 
(79%).  
 
3.3.4. Share of pharmaceutical expenditures due to brain disorders  
According to the ATC (anatomic–therapeutic classification) system, drugs are categorized by 
the target organ and mode of action, and statistics on pharmaceutical sales are typically 
provided based on this system. Through the ATC codes it is possible to identify drug classes 
used to treat disorders of the brain; however assumptions need to be made in some cases.  
As an example, in Sweden the total pharmaceutical expenditures in 2010 was SEK 35.6 
billion (in pharmacy sales prices, AUP) (Pharmacy Sales Prices (AUP) 2010. 
http://www.apotekensservice.se/Global/Externa%20webben/statistik/L%c3%a4kemedel%202
010/L%c3%a4kemedelsutvecklingen%202008-2010%201.0.pdf). Table 15 lists the 
expenditures on ATC groups that may be (partially) related to brain disorders. In a 
conservative scenario presented in Table 15, we only include costs for drug classes that are 
certain to be related to brain disorders.  
For a more realistic scenario (Table 16), we need to make assumptions regarding the use of 
cytotoxic drugs, anti-infectives and analgesics due to brain disorders.  
In Sweden in 2009, 2% of all incident cases of cancers were tumors of the central nervous 
system. Although the use and cost of chemotherapy will vary between tumor types, we 
assume 2% of the costs of chemotherapy may be attributed to cancers of the central nervous 
system.  
The share of costs for anti-infective drugs used to treat infections of the central nervous 
system is difficult to estimate. In 2009, there were 101,583 hospital admissions in Sweden 
where the primary diagnosis was an infection at any site. Out of these, 1985 (2%) were 
identified as CNS infections. Though antibiotic use is not directly related with hospital 
admissions, we assume that 2% of the costs for anti-infectives are used to treat CNS 
infections.  
The use of analgesics due to primary brain disorders is even harder to estimate — we assume 
up to 10% of this cost may be associated with brain disorders.  
In conclusion, we estimate that about 16% of total pharmaceutical expenditures are due to 
brain disorders (SEK 5.5– 5.8 billion in 2010). At the European level, this would correspond 
to about €30 billion, as total pharmaceutical expenditures are in excess of €180 billion 
(OECD, Health at a glance: Europe 2010) (OECD statistics 2011. http://www.oecd-
ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2010/pharmaceutical-
expenditure_9789264090316-45-en).  
There are a number of limitations to this analysis. We have completely excluded 
cardiovascular drugs (ATC class C, total cost SEK 3.1 billion). These drugs are in part used to 
treat cerebrovascular disorders; however the proportion is difficult to estimate.  
 
3.4. Validation of results  
 
3.4.1. Total healthcare expenditure  
The total healthcare expenditure in Europe in 2008 was €1222 billion (OECD statistics 2011 
http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT), which by an inflation rate 
of 3.1% should have increased to €1260 billion in 2010. Our estimate of the total direct 
healthcare cost of disorders of the brain in 2010 constitutes 24% of this healthcare 
expenditure. The previous EBC study estimated that the total cost of the disorders of the brain 
constituted 15% of the healthcare expenditure at that time (Andlin-Sobocki et al., 2005).  
A review of the literature on the direct healthcare cost of epilepsy suggested that they 
constitute between 0.12 and 1.12% of the total healthcare expenditure (Kotsopoulos et al., 
2001). In Europe this would imply a range between 1.5 and 14 billion [hlth_sha1h] (Eurostat 
2011. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_sha1h&lang=en). Our 
estimate of €6.5 billion places itself neatly in the middle of this range. Similarly, Evers et al. 
(2004) suggested in their review on the direct healthcare cost of stroke that they constitute 3% 
of the total healthcare expenditure, equal to €38 billion for Europe which is comparable to our 
estimate of €42 billion.  
 
3.4.2. Comparison to other European reviews  
Wimo et al. (2010) published another ambitious review on the overall cost of dementia in 
Europe. They estimated the total cost of dementia in EU27 at €160 billion in 2008. This is 
about 60% higher than our estimate which is explained by both higher prevalence and cost 
estimates in their analysis. They estimated the number of persons with dementia in EU27 at 
7.2 million compared to 6.3 million in our study. Their estimate was based on similar data to 
ours but instead of considering country specific estimates they calculated mean estimates by 
age and gender for Europe as a whole. They also estimated that the cost per person is €22,194 
compared to €16,584 in our study. The higher estimate is largely due to higher informal care 
costs constituting 55% of their total cost compared to 8 to 64% in our review depending on 
country. Informal care costs are known to be higher in Southern Europe compared to Northern 
or Western Europe (Gustavsson et al., 2010), and this was accurately reflected in Wimo et al. 
However, because comparatively little data are available for Southern Europe, the median 
approach employed in this study resulted in comparatively lower estimates. This is a 
limitation of the chosen approach but necessary to keep a consistent methodology across all 
disorders of this study.  
When comparing the results of our study with a prospective, naturalistic observational study 
conducted in 12 European countries (ICTUS study), aiming to estimate and compare the costs 
of formal and informal care of patients with Alzheimer's disease (Gustavsson et al., 2010), the 
cost per person estimated from our study is higher (€16,584 compared with €8000). This can 
be explained by the ICTUS study including a milder patient population; when looking at the 
more severe subgroup in the ICTUS study, the average cost per person was estimated at 
around 13,000–20,000 EUR depending on region, which is comparable with the cost per 
person estimated by our study.  
Kobelt G. and F. Kasteng conducted a similar review in 2009 on the cost of multiple sclerosis 
in Europe (Kobelt and Kasteng, 2009. 
http://www.comparatorreports.se/Access%20to%20MS% 20treatments%20-
%20October%202009.pdf). They estimated the total cost in Europe (EU27+3) at €14.9 billion 
which is just slightly higher than our estimate of €14.6 billion. Their estimate was based on 
470,000 persons above the age of 19 years resulting in an average cost of about €31,000 per 
person. This may be compared with our estimates; 440,000 persons from 18 years and above 
each with a mean cost of about €33,000. As in the comparison of the estimates for dementia, 
there were methodological differences between the 2009 review and ours but the results were 
in this case similar.  
 
3.4.3. Comparison to US evidence  
A search was conducted in PubMed identifying published reviews on cost of illness studies 
conducted in the United States. The reported estimates were converted into PPP-adjusted Euro 
in 2010 values and presented per capita (Table 17). The US estimates were compared side by 
side to our results per capita for Germany, which was selected as a comparable country to the 
US.  
The majority of the US estimates are higher than our estimates for Germany, and there are a 
number of explanations for this depending on the disorder. The US cost studies show 
comparable costs per person with ADHD to the Dutch study that our estimates were based on. 
However, we assumed that only 25% of persons with ADHD get treatment and therefore incur 
these costs while no such adjustment was done in the US. Therefore, our estimate for 
Germany is lower than the presented range for the US. For bipolar disorder, the indirect costs 
are similar in the US and Germany, but the direct costs seem higher in the US. The higher 
estimate for opioid dependence is explained by higher indirect costs in the US, which is in 
part explained by inclusion of indirect costs of premature mortality. The available estimate for 
schizophrenia in the US was comparable to our estimate of all psychotic disorders. The cost 
per person was therefore about twice as high as the German estimate. This was partly 
explained by the inclusion of costs of criminality, research, premature mortality, and 
presenteeism in the US estimate, together constituting about 10% of the total cost, but the 
largest difference was seen in much higher direct healthcare costs in the US.  
The available US estimates for anxiety disorders and sleep disorders were similar to the 
German results, although no estimates of the indirect costs were found for sleep disorders. 
The costs of migraine and mood disorders were lower in the US compared to Germany. The 
methods used for the US estimate for migraine was not available from the referenced 
publication and we can therefore not explain the discrepancy from our study. The two US 
studies on mood disorders are from the early nineties and they suggest that their estimates 
represent a lower limit of the true costs at the time.  
The proportions of direct and indirect costs to total costs are similar in the US and Europe. In 
both Germany and the US, a larger proportion of direct costs are seen in anxiety disorders 
whereas indirect costs constitute the majority of costs in mood disorders.  
Overall, the comparison to US estimates show that health care costs are higher in the US than 
in Europe. If anything, this indicates that the results of our study should rather represent an 
underestimation of the true cost than an overestimation. The comparison also supports the 
notion that health care costs are generally higher in the US compared to Europe.  
 
3.4.4. Comparison with European estimates of other major groups of disorders  
The cost of disorders of the brain is higher than all other comparable disease areas. The 
European Heart Network reported that the cost of cardiovascular disease was €192 billion in 
the EU in 2008 (European Heart Network 2008. http://www.ehnheart.org/publications/annual-
reports.html). The direct health care cost of cancer was estimated at €54 billion in 2005, while 
the indirect cost was suggested to be twice as high (Wilking and Jönsson, 2005). Another 
study suggested 6.3% of the total health care expenditure in Europe to be attributable to 
cancer on average (Wilking N et al. 2009. 
http://www.comparatorreports.se/Cancer%20report%20EFPIA%20Final%20summary%20sli
des% 20Jan%2027.pdf), which would result in medical costs of €79 billion in 2010. The total 
cost of cancer in Europe may therefore lie in the range of €150–250 billion. The direct health 
care cost of type II diabetes ranges between 1.6 and 6.6% in Europe (Jonsson, 2002), which 
equals €20 to €83 billion in 2010. The European cost of rheumatoid arthritis was estimated at 
€25 billion in 2008 (Kobelt G et al., 2009. 
http://www.comparatorreports.se/RA%20Barrier%20Report_FINAL_ 050110.pdf), and the 
cost of chronic obstructive pulmonary disease at €39 billion in 2006 (Halpin, 2006).  
 
 
4. Disorder specific sections  
 
4.1. Addictive disorders  
 
Substance-use disorders in general refer to hundreds of specific diagnostic classes stratified 
by the type of substance (ranging from opiates to caffeine to alcohol and nicotine) as well as 
the specific clinical diagnostic condition (ranging from intoxication, over delirium and 
withdrawl syndrome to abuse and dependence). For our survey only few classes of substances 
could be considered, namely alcohol, opioid drugs and cannabis as well as only two types of 
diagnoses, namely abuse and dependence. The epidemiologic and cost-of-illness studies 
focusing on the problem of substance abuse and dependence that have been conducted in 
Europe have been using different definitions to describe the problem of substance abuse or 
dependence in the population, which renders the comparison of their results difficult. 
Therefore, for the purpose of this study, the consumption of substances that is linked with 
harmful use and dependence was considered a relevant definition for the estimation of the 
burden of the disorder in Europe.  
 
4.1.1. Epidemiologic data review  
For alcohol dependence, prevalence estimates for three different regions in Europe (eastern, 
central and western) were calculated based on data available in the literature (de et al., 2006, 
2011; Florescu et al., 2009; Hansen et al., 2011; Latvala et al., 2009; Rehm et al., 2005; The 
Health and Social Care Information Centre 2009. 
http://www.ic.nhs.uk/webfiles/publications/alcoholeng2009/Final%20Format%20draft%2020
09%20v7.pdf; Uhl et al., 2009). For countries with no surveys, we based our estimates on the 
WHO calculations (WHO Europe 2010. 
http://www.euro.who.int/__data/assets/pdf_file/0004/128065/e94533.pdf). Country specific 
mean prevalence estimates for all ages above 15 years were calculated based on the 
population size of each age group in each country. The weighted mean for Europe was 3.4% 
but country specific estimates were used in the European cost model (ranging between 3.2 and 
4.1).  
In opioid and cannabis dependence, information was used from ongoing data collection done 
by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EU member 
states annually report to the EMCDDA epidemiological data from national surveys in the 
adult population, based on a “model questionnaire”. For this analysis the data from most 
recent national surveys were used (European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 2010. http://www.emcdda.europa.eu/stats10).  
Age dependent prevalence rates for cannabis and opioid dependence were considered as 
displayed in Table 18 because of the differences in prevalence by age group.  
 
4.1.2. Cost data review  
The search in the literature performed identified four new studies for alcohol (Balakrishnan et 
al., 2009; Jarl et al., 2008; Konnopka and Konig, 2007; Saar, 2009) in addition to the eight 
studies identified in the previous EBC study (Andlin-Sobocki and Rehm, 2005). The new 
studies that were identified used a similar methodology to estimate the economic burden of 
high alcohol consumption/abuse. Using alcohol-attributable fractions the cost per patient per 
year was calculated based on the total cost reported in the papers, divided with the number of 
patients with the disorder (calculated based on the prevalence estimates and the reference 
population). In order to avoid aggregating results from studies that used different 
methodologies and definitions of the disorder, only the cost estimates from the four new 
studies that used a similar methodology were included in the calculation of the burden of 
alcohol dependence in Europe (Table 19).  
Only one new cost-of-illness study (Godfrey et al., 2004) measuring the economic burden of 
dependence to opioids in the UK was found through the literature search. Out of the four other 
studies that were identified in the previous EBC study (Coyle et al., 1997; Fenoglio et al., 
2003; Garcia-Altes et al., 2002; Healey et al., 1998) only two were considered relevant for 
inclusion since they reported results for France and Spain (Fenoglio et al., 2003; Garcia-Altes 
et al., 2002) The other two studies were conducted in the UK, thus the latest study by Godfrey 
et al.(2004) that also reported the cost per patient for the UK was chosen as the most relevant 
to be used. The studies for France and Spain used a top–down methodology and estimated the 
economic burden of opioid addiction; therefore the cost per patient was calculated by dividing 
the total cost reported in the papers with the number of patients with opioid addiction in 
Europe (based on the prevalence estimates).  
No European studies on cannabis abuse/dependence were identified in the review. In the 
EBC2005 study, cannabis dependence was grouped together with opioids (the subgroup was 
referring to dependence to illicit drugs); however, the study by Healey et al. (1998) that 
measured the economic burden of illicit drugs in the UK did not include in the study 
population individuals with cannabis dependence/abuse. Therefore, specific cost estimates for 
cannabis abuse/dependence were not taken into account when calculating the burden of 
substance use disorders in Europe in 2010.  
 
4.1.3. Discussion  
The latest epidemiologic evidence for alcohol dependence, shows an increase in the number 
of patients with the condition, whereas the prevalence for opioid and cannabis dependence 
remains unchanged.  
The estimates of cost per person are lower in this review than the ones presented in the 
EBC2005 study (Andlin-Sobocki et al., 2005). In alcohol dependence, this is partly explained 
by lower estimates in countries where there was previously no data (Sweden and Estonia) 
although one might dispute whether this is simply a methodological artifact. Another 
explanation that is evident from our methodological approach is that as we divided the total 
cost estimates that were reported in the available studies by the number of persons to get the 
cost per person, since the number of persons has increased while there is no evidence of a 
proportional increase in total costs, the cost per person consequently gets lower. In opioid 
dependence the decrease is explained by new data from France and Spain which shows lower 
costs per person.  
It should be also highlighted that our estimates for addiction are conservative due to limiting 
the cost modeling to dependence to substances (Wittchen et al., 2008).  
 
4.2. Anxiety disorders  
 
The EBC2005 study considered 6 anxiety disorders, namely agoraphobia, generalized anxiety 
disorder (GAD), obsessive compulsive disorder (OCD), panic disorder, social phobia and 
specific phobias (Andlin-Sobocki et al., 2005). In this review we were able to also consider 
the evidence of the burden and costs of post-traumatic stress disorder (PTSD) (Wittchen et al., 
2009b).  
 
4.2.1. Epidemiologic data review  
In 2005, country specific estimates were considered for all anxiety disorders where available 
(Andlin-Sobocki and Wittchen, 2005b). In this revision, we assume that differences across 
studies from various European countries are primarily explained by methodological factors 
such as design issues whereas the true differences across countries are small. Therefore, we 
have considered the median European best estimates of the prevalence rates for all countries. 
This resulted in small changes in the prevalence estimates of individual diagnoses. Further, 
the best estimate for agoraphobia was set to 2% compared to 1.3% in the EBC2005 study. 
Age dependent prevalence rates were considered for GAD and PTSD (Table 20).  
A wider age range was considered for all anxiety disorders (Beesdo et al., 2010) in 
comparison to the EBC2005 study in which only adults between 18 and 65 were included 
(Andlin-Sobocki et al., 2005). However, our cost estimates were not assumed to be applicable 
to the full age range for many diagnoses as indicated in Table 20.  
 
4.2.2. Cost data review  
Six new relevant cost studies were identified in the literature review (Acarturk et al., 2009; 
Batelaan et al., 2007; Patel et al., 2002; Priebe et al., 2009, 2010; Smit et al., 2006), adding to 
the three studies considered in the EBC2005 study (Salvador-Carulla et al., 1995; Souetre et 
al., 1994; Zambori et al., 2002). At that time, data from a community based survey in 
Germany [GHS–MHS, (Jacobi et al., 2002)] was selected for estimation of the cost of anxiety 
disorders. These data was considered more reliable than those presented in any of the three 
published studies.  
Five of the newly identified studies report costs on individual diagnoses: two on social phobia 
(Acarturk et al., 2009; Patel et al., 2002), two on PTSD (Priebe et al., 2009, 2010), and one on 
panic disorder (Batelaan et al., 2007). The sixth study (Smit et al., 2006) reports costs for all 
anxiety disorders considered in this study except OCD and PTSD.  
Three studies (Acarturk et al., 2009; Batelaan et al., 2007; Smit et al., 2006) were based on a 
Dutch population-based cohort (NEMESIS) including a questionnaire administered to patients 
to assess their resource utilization. They all present relatively high costs which may at least in 
part be explained by a broader inclusion of cost items, but they do not provide sufficient 
information to make their estimates fully comparable to e.g. the GHS–MHS data (Jacobi et 
al., 2002). The three studies use varying methodology to estimate the cost caused by each 
respective disorder. Patel et al. (2002) reports costs for social phobia in the UK, based on data 
from 63 patients, who were identified through a community survey. The two articles by 
Priebe et al. (2009, 2010) present bottom–up estimates of the cost of Yugoslavian war 
refugees, diagnosed with PTSD and currently residing in the UK, Germany or Croatia. Priebe 
et al.(2010) reported costs for Croatia and other former Yugoslav republics, and these data 
were therefore selected for Slovenia.  
In exempt from the new data on PTSD, the GHS–MHS study (Jacobi et al., 2002) was 
preferred to all other identified studies on anxiety disorders. The main rationale was that there 
is considerable overlap between individual anxiety disorders (Wittchen et al., 2009a), and the 
German data allowed for calculation of the excess cost of each individual diagnosis. This was 
done by calculating the difference in resource use between patients with and without each 
individual anxiety disorder in the community-based cohort (Table 21).  
The PTSD study indicated a 10% overlap with other anxiety disorders. The estimates for 
PTSD were therefore deducted by 10% in the European cost model to adjust for this overlap.  
 
 
 
 
4.2.3. Discussion  
The same cost data was selected as in the EBC2005 study (Andlin-Sobocki et al., 2005). 
However, recalculations of excess costs were performed to avoid double counting due to 
overlapping anxiety disorders, which resulted in somewhat higher estimates in most groups.  
 
4.3. Brain tumors  
 
Primary brain tumors represent 2% of all cancers (Ferlay et al., 2010) and are a diverse group 
of tumors with marked differences in etiology, treatment and prognosis (Bondy et al., 2008; 
DeAngelis, 2001; Wrensch et al., 2002). In children, central nervous system (CNS) tumors 
represent 15–25% of all tumors (Packer et al., 2008; Stiller and Bunch, 1992). While the 
treatment of meningioma has not consistently changed in recent years, the state of the art 
therapy in high grade glioma is currently surgery followed by radiotherapy with concomitant 
and adjuvant temozolomide (Stupp et al., 2005). These treatment changes have led to an 
increase of quality of life and average life expectancy accompanied by higher costs (Louis et 
al., 2007).  
 
4.3.1. Epidemiologic data review  
The review included the ICD10 diagnoses C70, C71, C72 (malignant brain tumors), D32, D33 
(benign brain tumors), and D42, D43 (brain tumors of unknown origin). The search terms 
included epidemiology (incidence, prevalence, mortality, survival), study design (registry, 
population-based, review), and disease specific terms (brain/intracranial/ cerebral 
tumor/cancer/neoplasm and specific tumor types). The most complete reference from a 
European perspective was the article by Ferlay et al., which used data from cancer registries 
and statistical models to estimate incidence and mortality data for 25 cancers in 40 European 
countries in 2008 (Ferlay et al., 2010). Prevalence figures were estimated from the 
NORDCAN database by looking at the ratio between the 5-year prevalence and the incidence 
in the Nordic data, which was 2.86 for men and 3.54 for women (Engholm et al., 2010). As 
the costs for cancer cases are often incurred over several years, we looked at the 5-year 
prevalence rather than the 1-year prevalence. Before the prevalence figures were calculated, 
the incidence figures from Ferlay et al. (2010) were adjusted to take benign tumors into 
account (ICD-10 codes D32–33). The incidence ratios between all central nervous system 
tumors (CNS) and the malignant tumors in the Nordic data were 1.66 for men and 2.71 for 
women. The difference between men and women reflects the different incidence, prevalence, 
and mortality ratios for malignant and benign tumors, with malignant glioma occurring 
slightly more frequently in men and benign meningioma more frequently in women (Louis et 
al., 2007) (Table 22).  
 
4.3.2. Cost data review  
A search for relevant cost literature was carried out using electronic database PubMed 
(MEDLINE). The search strings were combinations of disease-specific search terms (brain 
tumor, glioma, meningioma, astrocytoma, schwannoma etc.) and search terms related to cost 
studies (costs, resources). The most complete study was by Blomqvist et al., as it included all 
relevant diagnoses and both direct and indirect costs (Blomqvist et al., 2000). Due to 
treatment changes in recent years, primarily the introduction of the temozolomide regimen in 
malignant glioma, the costs in Blomqvist et al.(2000) do not accurately represent the current 
standard therapy for high grade glioma. The study by Wasserfallen et al. (2005) considered 
the temozolomide regimen for patients with malignant glioma. The study by Latif et al. 
(1998) was excluded because it was published before the introduction of the temozolomide 
regimen in malignant glioma and does not represent the current treatment cost. The study on 
the cost of intracranial pathology by Wellis et al.(2003) was excluded because some of the 
diagnoses were outside of the scope of the EBC review. Separate costs for the different 
subgroups were not reported. Seventy-three percent of the indirect costs in Blomqvist et al. 
(2000) were associated with premature mortality and were excluded from Table 23.  
 
4.3.3. Discussion  
The Ferlay publication included the ICD-10 diagnoses C70–72 (malignant CNS tumors) 
(Ferlay et al., 2010). The NORDCAN data were used in order to extend the estimate to 
include benign CNS tumors (D32, D33) (Engholm et al., 2010). Compared with the data in 
Europe in 1995 (Bray et al., 2002) used in the EBC2005 study (Andlin-Sobocki et al., 2005), 
the average incidence of primary brain tumors has increased by about 5%. However, this 
might be an effect of better diagnostic imaging methods and more comprehensive reporting 
rather than a true increase in the incidence of brain tumors in the population. Both direct and 
indirect costs have increased and will increase even more in the next few years by the 
introduction of new chemotherapy options as standard methods in the treatment of malignant 
brain tumors. Costs for premature mortality (73% of the indirect costs in Blomqvist et al.) 
were included in the EBC2005 study, but not in this update.  
 
4.4. Dementia  
 
Recent developments in dementia research have included revised diagnostic criteria, the use 
of biomarkers in diagnosis, disease course prediction and treatment evaluation; and the search 
for new potent drug treatments. All these efforts may eventually lead to inventions that can 
change the state of the art in dementia care and consequently also the burden of dementia. 
However, although there have been new studies, the patterns of dementia care in Europe 
today are similar to those 5 years ago. Therefore, dramatic changes in the number of patients 
or the cost of dementia in recent years are not expected.  
 
4.4.1. Epidemiologic data review  
Population based studies, with a cross sectional design, reporting the prevalence of dementia 
were identified by a structured search in PubMed (MEDLINE). Seventeen relevant studies 
were identified reporting prevalence estimates by age, gender and severity, although 
incomplete for many studies (Abela et al., 2007; Andersen et al., 1997; Bdzan et al., 2007; 
Börjesson-Hanson et al., 2004; Brayne, 2006; De Ronchi et al., 2005; Gascon-Bayarri et al., 
2007; Gostynski et al., 2002; Helmer et al., 2006; Kurz et al., 2001; Ott et al., 1995; Rahkonen 
et al., 2003; Riedel-Heller et al., 2001; Tognoni et al., 2005; Tsolaki et al., 1999). In 2005, 
only persons above 65 years of age were considered (Jönsson and Berr, 2005), while in this 
revision we included everyone from 60 years of age. The overall prevalence in each country 
was calculated by multiplying the prevalence estimates in Table 24 by the population size of 
each of these age groups in each country, and dividing the sum of these products by the total 
population above 60 years of age. The European mean (weighted by the sample population 
size of each study) was used for countries where no data were available. The prevalence 
estimates reported for those between 85 and 90 years of age were assumed for everyone above 
85 years because of limitations in the available data on population sizes in the elderly.  
 
4.4.2. Cost data review  
The cost data literature review resulted in 13 relevant cost studies (Boada et al., 1999; 
Coduras et al., 2009; Gustavsson et al., 2011; Jönsson et al., 1999, 2006; Kronborg et al., 
1999; Lopez-Bastida et al., 2006; Mesterton et al., 2010; O'Shea and O'Reilly, 2000; Rigaud 
et al., 2003; Schulenberg et al., 1998; Scuvee-Moreau et al., 2002; Wolstenholme et al., 2002) 
in addition to the 6 studies identified and selected for the EBC2005 study (Jönsson and Berr, 
2005). Most were bottom–up studies with a one-off interview with caregivers of patients with 
Alzheimer's disease, but the mix also included registry studies, prospective cohorts and a 
broader study sample of demented elderly.  
Some of the identified studies were excluded due to the following limitations. Three studies 
presented outlying and outdated estimates (Cavallo and Fattore, 1997; Souetre et al., 1995). 
Another four only provided total costs or costs by severity with insufficient information on 
what resources or patient samples they referred to (Atance Martinez et al., 2004; Francois et 
al., 2004; Livingston et al., 2004; Trabucchi, 1999). Finally, one study was excluded because 
it was based on a small Swedish sample of patients with dementia with Levy bodies, with 
relatively high costs and therefore not representative to the general dementia population 
(Boström et al., 2007).  
The remaining 15 studies provided country specific estimates for the European cost model 
(Table 25). Unweighted means were calculated for countries with data from several studies. 
Three studies were not reporting any data on informal care but contributed with other direct 
health care and non-medical costs (Jönsson et al., 1999; Kronborg et al., 1999; Wolstenholme 
et al., 2002).  
 
4.4.3. Discussion  
The cost of informal care is uncertain and varies largely across studies, which to a great extent 
is due to the lack of established methods to assess and value this resource. Another source of 
uncertainty is the selection of study persons. The degree of severity and the proportion of 
persons residing in special accommodation vary across studies and is probably a reflection of 
the sampling of persons rather than the true distribution of the target population in most 
studies. Population based samples may provide a solution, but very large samples would be 
needed to get stable results.  
The cost per person with dementia is higher overall in 2010 than previously reported in our 
2005 study (Andlin-Sobocki et al., 2005). All 10 new included studies report higher mean 
costs than the 5 studies included in 2005 (Jönsson and Berr, 2005). Whether this reflects an 
increase in the actual cost of dementia is doubtful because of the uncertainties related to the 
cost of informal care, and the sample selection. Recent estimates include more studies 
conducted in southern Europe (Spain and France) where informal care is more common, 
whereas in northern Europe (Sweden and the UK), the recent studies have included a larger 
proportion of patients in residential care settings. This has led to an increase in the direct non-
medical cost estimates which explains most of the change in the cost per person overall.  
 
4.5. Epilepsy  
 
The worldwide annual incidence of epilepsy ranges from 16 to 51 per 100,000 (Banerjee et 
al., 2009). The age-specific prevalence is slightly different in children and adolescents (4.5–5 
per 1000), adults (6 per 1000), and in the elderly (7 per 1000). The age-specific incidence 
tends to vary significantly according to age. It is high in children and adolescents (70 per 
100,000), stabilizes in adults (30 per 100,000), and increases in the elderly (100 per 100,000) 
(Forsgren et al., 2005b). The prevalence of the disease is slightly higher in males than in 
females, although the absolute difference is usually small and most studies show shifting rates 
between the sexes in different age groups (Bielen et al., 2007; Brodtkorb and Sjaastad, 2008).  
 
4.5.1. Epidemiologic data review  
The search terms used in the electronic database PubMed included epidemiology (incidence, 
prevalence, mortality), study design (registry, population-based, review) and disease specific 
terms (epilepsy, seizure, status epilepticus) in combination with a list of European countries. 
Only studies published in 2004 or later were included in the search, as a previous review 
covered publications up to the spring of 2004 (Forsgren et al., 2005a). After review, 16 recent 
studies (Adelow et al., 2009; Benavente et al., 2009; Bielen et al., 2007; Brodtkorb and 
Sjaastad, 2008; Christensen et al., 2007; Dura-Trave et al., 2008; Gallitto et al., 2005; Gao et 
al., 2008; Kotsopoulos et al., 2005; Larsson and Eeg- Olofsson, 2006; Linehan et al., 2010; 
Löfgren et al., 2009; Olafsson et al., 2005; Picot et al., 2008; Stranjalis et al., 2009; Svendsen 
et al., 2007) were included in addition to those identified in the EBC2005 study (Table 24). 
Prevalence rates were available from 11 recent studies not included in the previous review 
(Forsgren et al., 2005a), and incidence rates from eight new studies (three of them also 
showing prevalence rates). A list of all identified prevalence studies is included in Table 26, 
sorted by age group and year of publication. The average prevalence is about the same in the 
studies published up to 2004 (4.9 per 1000) and the studies published after 2004 (5.1 per 
1000). The median prevalence in studies including all ages was 5.3 per 1000, while the 
median prevalence in studies including children and adolescents was 4.0 per 1000 and in 
studies including adults and elderly 6.5 per 1000.  
 
4.5.2. Cost data review  
A search for relevant cost literature was carried out using the PubMed database. The search 
strings were combinations of disease-specific search terms (epilepsy, seizure, status 
epilepticus etc.) and search terms related to cost studies. The search included articles 
published between January 1995 and December 2010. Studies on the cost of illness of 
epilepsy in Europe were available from France, Germany, Italy, the Netherlands, Spain, 
Sweden, Switzerland and the UK (Beghi et al., 2004; Berto et al., 2000; Cockerell et al., 1994; 
De Zélicourt et al., 2000; Gessner et al., 1993; Guerrini et al., 2001; Hamer et al., 2006; 
Jacoby et al., 1998; Kotsopoulos et al., 2003; Sancho et al., 2008; Swingler et al., 1994; Tetto 
et al., 2002; van Hout et al., 1997) (Table 25). A limitation in the data is that it is often 
difficult to distinguish whether the epilepsy-specific costs have been separated from costs for 
co-morbidities. The costs may therefore represent the average cost of patients with epilepsy 
rather than the epilepsy-specific costs. Status epilepticus is an importance source of direct 
costs; however, no cost-of-illness studies in which this seizure category was assessed 
separately seem to be available in Europe. A further evidence gap is that not all studies of 
adult patients include indirect costs due to productivity losses. In general, the costs depend 
primarily on seizure frequency and responsiveness to drug treatment. Newly diagnosed 
patients also tend to have higher costs, and clinic-based samples can be expected have higher 
costs than population-based samples (Table 27).  
 
4.5.3. Discussion  
A number of new studies on the epidemiology and cost of epilepsy have been published in 
recent years. These studies largely confirm the findings from the EBC2005 study (Andlin-
Sobocki et al., 2005).  
 
4.6. Headache  
 
Headaches are among the most common health disorders worldwide. Although most sufferers 
experience mild symptoms, some attacks are highly disabling and come at large societal costs. 
The EBC2005 report on the cost of headache disorders only included migraine, because the 
costs of tension-type headache, medication overuse headache and other headaches were 
virtually unknown in Europe at the time (Berg and Stovner, 2005). Since then, Eurolight, a 
comprehensive study estimating the prevalence and economic burden of all headache 
disorders in Europe, has been undertaken (Andrée et al., 2011; Linde et al., 2011).  
 
The Eurolight project, initiated by CRP-Santé Luxembourg is a recent, multinational 
population-based observational study, assessing the prevalence and impact of all headache 
disorders in Europe. More than 8000 questionnaires from eight countries (Lithuania, 
Germany, The Netherlands, Luxembourg, Italy, Austria, France and Spain) were collected 
(Andrée et al., 2011; Linde et al., 2011).  
 
4.6.1. Epidemiologic data review  
Prevalence estimates of headache in available European epidemiological studies have been 
reviewed recently (Stovner and Andree, 2010). The one-year prevalence of migraine 
(estimated at 15%) was considered to be well established from the evidence identified.  
For non-migrainous headaches the published evidence on prevalence is more scarce and the 
available studies have varying designs. However, the Eurolight project offers oneyear 
prevalence rates of tension-type headache (TTH), medication overuse headache (MOH), and 
“other headaches” (i.e. neither tension-type headache, migraine or medication overuse 
headache), collected with a common robust methodology in a large sample from eight 
European countries. Single diagnoses were assigned hierarchically (i.e. subjects indicating 
multiple headaches were assigned only one; primarily MOH followed by TTH and migraine). 
This is necessary in economic studies to avoid double counting, but it is contrary to clinical 
diagnosis where all types of headache in an individual should be diagnosed. The great 
majority of persons diagnosed with MOH have migraine as the underlying condition. The 
prevalence estimates were further reduced to adjust for overestimation due to a potential 
interest bias of responders, suggested after additional analysis of non-respondents in four of 
the Eurolight countries. The prevalence estimates are shown in Table 28.  
 
4.6.2. Cost data review  
The literature review resulted in two new relevant studies since EBC2005 (Linde et al., 2011; 
Pradalier et al., 2004). Pradalier et al. (2004) reported direct costs and work absenteeism for 
migraine and other episodic headaches in France based on interviews from a population based 
sample of 1486 subjects. Linde et al. (2011) reported in the Eurolight study direct and indirect 
costs for 6551 subjects in their multinational sample.  
The Eurolight data were selected for the cost model because it would enhance the 
comparability across countries as data for all eight countries (whose populations constitute 
55% of the EU27 population) were collected within the same study. Further, Pradalier did not 
present any estimate of indirect costs but only the number of absent days (Pradalier et al., 
2004), and the direct costs were comparable to those in the Eurolight study (Linde et al., 
2011) (e.g. €128 per person with migraine in Pradalier compared to €86 in Eurolight).  
The Eurolight study included high costs due to presenteeism (i.e. reduced productivity while 
at work). This productivity loss is undoubtedly an important indirect cost to society, but it is 
difficult to measure and generally not reported in studies on costs of disorders of the brain. 
For consistency across the disorders, a conservative approach was therefore selected for this 
review and it was decided not to include presenteeism in the main results. Due to the small 
sample sizes of patients with MOH and other headaches, we only considered the mean for all 
countries as inputs in the model. In the model, Spain and France were selected as base 
countries for MOH and other headaches respectively because they had two of the largest 
numbers of subjects in the Eurolight study (Linde et al., 2011) and their individual estimates 
were similar to the selected means. The final estimates for the cost model are shown in Table 
29.  
 
4.6.3. Discussion  
The Eurolight report enables estimation of the prevalence and costs associated with non-
migrainous headaches, which were not included in 2004. The indirect costs dominate total 
costs and are especially high in MOH, which also has the highest direct healthcare costs. The 
costs per subject with migraine in the eight countries range between 100 and 800 Euro (mean 
of €445) which is lower than the estimates considered in 2004 (€590 on average) but higher if 
excluding presenteeism from the 2004 estimate (valued at €294 in 2004). This may be due to 
the hierarchical approach used in Eurolight under which comparatively expensive subjects 
with both MOH and migraine were assigned to the MOH group, whereas they were likely 
included in the estimates from previous studies on subjects with migraine (Linde et al., 2011; 
Pradalier et al., 2004).  
Data on cost from the Eurolight study are yet to be published. Although the present study has 
graciously been allowed to use Eurolight data for input into our model, the data presented 
here and the data to be published from Eurolight will differ. In addition to the per subject 
costs in the eight included countries, Eurolight estimated the total costs in these countries, and 
extrapolated to the 27 European Union member states (Linde et al., 2011). Our per subject 
cost estimates differ from theirs because we opted for a more conservative approach in which 
we excluded presenteeism. Further, their methods for extrapolating costs to other European 
countries which were not included in the data collection differed from ours. They extrapolated 
the total costs in the eight countries to EU27 assuming that the costs in the included countries 
were the same as in those not included (Linde et al., 2011). In contrast, we extrapolated the 
median per subject cost in the included countries to EU27+3, adjusting for differences in 
health care expenditure and income levels. Further, Eurolight presented costs in nominal 
values (Linde et al., 2011) whereas our estimates are presented in PPP adjusted real Euro. 
There is no right or wrong in the selection of these two approaches. Extrapolation of data 
from one country to another will always need to rely on a set of assumptions. The approach 
used in the Eurolight study is simple and straight forward and thereby easy for the reader to 
follow, whereas the more complex approach selected for this review has the advantage of 
taking known differences between countries into account. Moreover, nominal estimates 
presented in the Eurolight study is more relevant for individual countries as they will be 
directly comparable to other local expenses, whereas estimates in real Euro is more relevant 
for comparison of resource use across countries as they remove the effect of price differences. 
Despite the methodological differences discussed above, the results are rather similar and 
there is no real discrepancy between the two studies. Excluding presenteeism, our per subject 
cost estimate of migraine is 9% lower than the mean cost per subject presented by Eurolight 
(Linde et al., 2011). This discrepancy is small compared to a more than fivefold difference 
between the per subject costs of migraine in France and Germany. The discrepancies are 
larger for the more rare diagnoses (our estimates are 24% higher in MOH and 59% lower in 
other headache), but these differences are also small in comparison to the differences across 
countries. In conclusion, the main uncertainty in the presented estimates is due to the large 
variation across countries as reported in the Eurolight study (Linde et al., 2011).  
 
4.7. Mood disorders  
 
From the wider spectrum of mood disorders (also labeled affective disorders), we included 
two particularly important diagnoses with large societal costs; namely major depression and 
bipolar disorder.  
 
4.7.1. Epidemiologic data review  
The epidemiologic evidence has not changed since 2004, with the exception of the prevalence 
estimates ofmajor depression in the elderly which is now assumed to remain on the same 
levels as in adults (Wittchen and Uhmann, 2010). In 2005, country specific estimates were 
used for both major depression and bipolar disorder (Andlin-Sobocki and Wittchen, 2005a). 
In this revision, we assume that differences across studies from various European countries 
are primarily explained by varying study designs whereas the true differences across countries 
are small. Therefore, we have considered the median European best estimates of the 
prevalence rates for all countries. That is, 6.9% for major depression (age 18+) and 0.9% for 
bipolar disorder (age 18–65). We acknowledge, though, that the prevalence estimate for 
bipolar disorder is extremely conservative, most likely to reflect bipolar 1 disorders (with full 
mania) only (Beesdo et al., 2009).  
 
4.7.2. Cost data review  
For major depression, nine new relevant studies were identified (Cuijpers et al., 2007; Friemel 
et al., 2005; Grabe et al., 2009; Hamre et al., 2008; McCracken et al., 2006; McCrone et al., 
2005; Salvador-Carulla et al., 2011; Sicras-Mainar et al., 2010; Smit et al., 2006) adding to 
the three studies selected in the EBC2005 study (Chisholm et al., 2003; Salize et al., 2004; 
Thomas and Morris, 2003). These 12 studies provided estimates for the Netherlands (Cuijpers 
et al., 2007; Smit et al., 2006), Germany (Friemel et al., 2005; Grabe et al., 2009; Hamre et 
al., 2008; Salize et al., 2004), the UK (McCracken et al., 2006; McCrone et al., 2005; Thomas 
and Morris, 2003) and Spain (Chisholm et al., 2003; Salvador-Carulla et al., 2011; Sicras-
Mainar et al., 2010). Where possible, the best available study was selected for each country.  
The two Dutch publications reported data from the same study, a population based cohort 
study (NEMESIS). Smit et al. (2006) was preferred because they presented costs for major 
depression while Cuijpers et al. (2007) compared severity subgroups.  
Four studies reported costs of depression in Germany, two of which presented their results in 
German (Friemel et al., 2005; Salize et al., 2004). The study by Salize et al. was selected in 
the previous EBC review. It is a bottom up COI study assessing the direct costs of depression 
in a sample of 270 patients with depressive disorder, who were recruited by primary care 
physicians, family doctors and psychiatrists (Salize et al., 2004). Friemel et al. (2005) 
reported direct health care costs for 131 persons with major or minor depression out of a 
community-based sample of 3555 non-institutionalized adults (ESEMED). In the third study, 
Hamre et al. (2008) reported both direct and indirect costs of unipolar depression patients 
based on 3 year follow up data from the Anthroposophic Medicine Outcomes Study (AMOS). 
In the fourth study, Grabe et al. (2009) reported direct health care costs for 1314 persons with 
depression out of a population-based cohort of 3300 persons from the Study of Health in 
Pomerania (SHIP). Grabe et al. was selected for Germany because it was based on a 
comparatively large population-based sample.  
Three studies reported costs in the UK (McCracken et al., 2006; McCrone et al., 2005; 
Thomas and Morris, 2003). Two studies were identified in this review (McCracken et al., 
2006; McCrone et al., 2005) and a third study was included from the previous EBC review 
(Thomas and Morris, 2003). McCrone et al. (2005) interviewed adults that had major 
depression in their childhood, and should therefore not be representative to all adults with 
depression. McCracken et al. (2006) reported costs of depression in five EU countries (UK, 
Ireland, Spain, Norway, Finland) based on the ODIN study (Outcomes of Depression 
International Network). Thomas and Morris is a top down COI study that reported direct and 
indirect costs of depression based on data from multiple patient registries in the UK (Thomas 
and Morris, 2003). Thomas and Morris was selected for the UK. Three studies presented costs 
for Spain (Chisholm et al., 2003; Salvador-Carulla et al., 2011; Sicras-Mainar et al., 2010). 
Two studies were identified in this review (Salvador- Carulla et al., 2011; Sicras-Mainar et 
al., 2010) and one study was included from the previous EBC review (Chisholm et al., 2003). 
Salvador-Carulla et al. (2011) is a top down study and estimated the costs of depression in 
Catalonia, based on a literature review of available estimates, secondary databases and expert 
opinions. Sicras-Mainar et al. (2010) is a bottom up COI study (published in Spanish) which 
was based on the data from two hospitals in Spain, in Badalona and Pujol. It reported direct 
health care and indirect costs of depression for a total of 4572 patients (54.6% were in 
remission), who were followed for 18 months. Chisholm et al. (2003) is a bottom up COI 
study based on data from Longitudinal Investigation of Depression Outcomes (LIDO). It 
reported direct and indirect costs of depression in five countries (Israel, Spain, Brazil, 
Australia and Russia). In Spain, 472 patients with four different types of depressive disorder 
(comorbid and discrete clinical and subclinical depression) were recruited from primary care 
settings. Given the sample populations in the other studies, the costs for comorbid clinical 
depression (98 patients) were considered most relevant. Sicras-Mainar et al. was selected for 
Spain because it is based on primary data on a relatively large sample of patients. Table 30 
shows the cost data used for major depression in the European cost model.  
For bipolar disorder, three new relevant studies were identified (Gonzalez-Pinto et al., 2010; 
Osby et al., 2009; Tafalla et al., 2010) adding to the four studies included in the EBC2005 
study (Das and Guest, 2002; De Zélicourt et al., 2003; Hakkaart-van et al., 2004; Olie and 
Levy, 2002). Five of these studies (De Zélicourt et al., 2003; Gonzalez- Pinto et al., 2010; 
Olie and Levy, 2002; Osby et al., 2009; Tafalla et al., 2010) reported direct healthcare costs of 
patients admitted to hospital or visiting outpatient clinics due to a manic episode. The 
remaining two studies (Das and Guest, 2002; Hakkaart-van et al., 2004) focused on the 
broader group of persons with bipolar disorder rather than only persons with manic episodes, 
and included both direct and indirect costs. Das Gupta and Guest was a top down study based 
on multiple British registries. Hakkaart-van Roijen et al. reported costs on 40 patients with 
bipolar disorder from a population based cohort (NEMESIS) in the Netherlands.  
The estimates presented by Das and Guest (2002) were considered for the European cost 
model, because of the broader group of persons with bipolar disorder, the inclusion of indirect 
costs and the limited sample size of the Dutch study. The indirect costs of mortality was 
excluded resulting in direct healthcare costs of £487, direct non-medical costs of £468 and 
indirect costs of £6663 (all in 1999 GBP).  
 
4.7.3. Discussion  
The direct health care costs of persons with major depression vary across studies and 
countries, and is probably explained both by differences in regional care patterns and study 
design. Not least the severity of persons has a large impact on the cost estimates, and top–
down registries may to a larger extent include the less severe and costly persons than bottom-
up studies. For instance, the British top–down study reports much lower estimates than the 
German populationbased bottom–up study. The pattern was similar in the EBC2005 study 
(Andlin-Sobocki et al., 2005), but lower estimates on the indirect costs in Spain and the 
Netherlands result in lower total costs overall. For bipolar disorder, no evidence of changes in 
costs has emerged since 2005.  
 
4.8. Multiple sclerosis  
 
Multiple sclerosis (MS) is the most common disease of the central nervous system causing 
permanent disability in young adults. The diagnosis of MS is made based on clinical history, 
neurological examination, diagnostic tests, and after the exclusion of other diseases that could 
account for the clinical, laboratory and radiological findings. MS typically presents with a 
clinically isolated syndrome (CIS), defined by a distinct first neurological event with observed 
demyelination involving the optic nerve, cerebrum, cerebellum, brainstem, or spinal cord.  
 
4.8.1. Epidemiologic data review  
The distribution of MS prevalence in Europe before 2004 was reviewed in the EBC2005 
study (Andlin-Sobocki et al., 2005). An increase in the prevalence estimates was observed 
since 2004, given the use of new diagnostic criteria which allow for detecting the disease 
earlier.  
Despite the wealth of epidemiological studies on MS conducted over the past decades, the 
picture of MS distribution by geography, gender and age is still affected by methodological 
concerns: (a) the variability of the surveyed populations (size, age structure, ethnic origin, 
etc.), (b) the capability to detect benign and/or early cases, (c) the degree of case 
ascertainment differing by geographical and calendar time setting, access to medical care, 
number of neurologists, availability of new diagnostic procedures, public awareness about 
MS, etc.; and (d) the impact of the different diagnostic criteria used across the studies.  
The reported point prevalence estimates for each country ranged from 56 per 100,000 in 
Lithuania to 232 in Ireland (Table 31). Some studies also reported prevalence estimates by 
age, gender and severity but they were not considered for the European cost model. Costs 
were only considered for those aged 18 years and above.  
 
4.8.2. Cost data review  
Regarding the review of the literature to obtain relevant cost information, fourteen recent 
studies met the predefined inclusion criteria and were selected for inclusion (Berg et al., 2006; 
Casado et al., 2006; Kobelt et al., 2006a,b,c; Kobelt, 2006; Kobelt et al., 2006d,e,f,g, 2009; 
McCrone et al., 2008; Orlewska et al., 2005; Russo et al., 2004) (Table 32). Ten of the 
fourteen studies were part of a multinational observational study in Europe, conducted by 
Kobelt and colleagues and therefore were all included in the calculations (Berg et al., 2006; 
Kobelt et al., 2006a,b,c; Kobelt, 2006; Kobelt et al., 2006d,e,f,g, 2009) (Table 30). Cost-of 
illness studies including MS patients from countries already covered by the European study 
by Kobelt and colleagues were excluded in order to avoid calculations based on studies with 
differences in methodology (Casado et al., 2006; McCrone et al., 2008; Russo et al., 2004). 
The study conducted by that presented the costs of MS patients in Poland was also included in 
the calculation of the cost of MS in Europe (Orlewska et al., 2005).  
Cost-of-illness studies conducted before 2004 and included the EBC2005 study, were not 
considered relevant for inclusion since the new treatment options that are available since 2004 
resulted in an increase in the cost per patient.  
In order to estimate the cost of Multiple Sclerosis for the entire population, costs for non-adult 
patients were set to zero given the lack of relevant data. This is a limitation which however is 
not likely to have an important impact on the results since there are very few non-adult MS 
cases and therefore the underestimation of the total economic burden should not be 
significant.  
 
4.8.3. Discussion  
The new prevalence data available for European countries suggest an increase of the disease 
frequency since the EBC2005 study (Andlin-Sobocki et al., 2005). This increase is likely to 
be attributed to the new diagnostic criteria which allow detecting the disease earlier. With 
regard to the economic evidence retrieved from the literature, an increase in the cost per 
patient with MS is observed, which is likely due to the new and more costly treatment options 
that are available during the last ten years. The differences in the methodologies of the cost-
of-illness studies that were conducted before and after 2004 as well as the differences in the 
disease severity of the study populations render the comparison between the studies difficult 
and limit the possible interpretation of the changes in the economic burden of the disease 
since 2004.  
 
4.9. Parkinson's disease  
 
Parkinson's disease is a chronic progressive neurodegenerative disorder characterized by 
tremor, bradykinesia, rigidity and postural instability. In parallel to the gradual loss of 
function, patients perceive a reduction in their quality of life and their need for care incurs 
high costs to their families and society as a whole. The number of persons and subsequently 
the burden of Parkinson's disease is expected to increase over time due to the aging European 
population. In the EBC2005 study, only persons above 65 years of age were considered 
whereas in this revision the costs of two age groups were estimated; one younger group (aged 
40– 69) with low prevalence but higher costs due to work absence, and one older (70+) in 
which the prevalence is higher but with no indirect costs because they are already retired.  
 
4.9.1. Epidemiologic data review  
Separate prevalence estimates were identified for persons between 40 and 69 years of age, and 
those of 70 years of age and above (Table 33). Estimates were only available for four 
countries but were assumed to be representative to the whole of Europe.  
 
4.9.2. Cost data review  
The review of the cost literature revealed eighteen studies that were considered relevant for 
inclusion. Four of these studies reported country-specific cost estimates for Germany, Austria, 
Italy and Czech Republic, out of a registry set up by the European network for Parkinson's 
disease (EuroPa) (European Network for Parkinson's Disease 2010. www. europarkinson.net). 
Persons were recruited from the EuroPa registry including outpatients at specialist clinics and 
their direct and indirect costs were assessed through a questionnaire at baseline and follow-up 
visits after 3 months (Reese et al., 2010; von Campenhausen et al., 2009; Winter et al., 
2010a,b). There were seven other studies conducted in these four countries but the EuroPa 
estimates were preferred because they used a common robust methodology (Barth et al., 2005; 
Dengler et al., 2006; Dodel et al., 1997, 1998; Ehret et al., 2009; Keller et al., 2003; Spottke et 
al., 2005).  
Among the studies that there were identified from the review of the literature, four studies 
reported relevant cost estimates for Finland, France, Sweden and the UK (Hagell et al., 2002; 
Keränen et al., 2003; LePen et al., 1999; McCrone et al., 2007). McCrone et al. (2007) 
estimated the costs of patients with Parkinson's disease in the UK that were recruited from a 
community based cohort and hospital clinics. The other three studies were also selected for 
the EBC2005 study and constitute the most up to date evidence on costs in their respective 
countries (Hagell et al., 2002; Keränen et al., 2003; LePen et al., 1999).  
The remaining three studies did not report any cost estimates relevant for our study. Two of 
them explored the effects of dyskinesias on direct health care costs (Maurel et al., 2001; 
Pechevis et al., 2005) and Cubo et al. (2005) studied the burden of Parkinson's disease in 
Spain in terms of years of life lost (YLL) and years lived with disability (YLD).  
The estimates considered for the European cost model are listed in Table 34. The direct costs 
per person are assumed to be the same for both age groups, but indirect costs are only 
considered for persons up to 65 years of age.  
 
4.9.3. Discussion  
This review of the prevalence and costs of Parkinson's disease in Europe enabled the inclusion 
of younger persons below the age of 65 which were not included in the EBC2005 study. 
However, because the prevalence in those below 70 years of age is relatively low, this is not 
expected to result in a large increase in the total number of persons. The updated costs per 
person are similar to those reported in the EBC2005 study albeit with some variation across 
countries; however, the new study included new evidence for a large number of countries.  
There is still limited data on costs separating between the young and the elderly persons with 
Parkinson's disease. The direct health care costs were therefore assumed to be the same across 
age groups, but it should be noted that most of the evidence is based on younger persons.  
 
 
 
 
4.10. Psychotic disorders  
 
Psychotic disorders are characterized by episodic or enduring dysfunctions of perceptual 
cognitive and emotional processes. Common symptoms include hallucinations and paranoid 
or bizarre delusions, associated with typical severe impairments and disabilities with regard to 
social and occupational functioning. Schizophrenia (ICD10 — F20) is the most severe type of 
disorder in this group, while others include schizoaffective disorder (ICD10 — F25.9) and 
schizophreniform disorder (ICD10 — F20.81). All psychotic disorders were included in the 
literature review, but we only considered estimates on the cost of persons with schizophrenia 
for the European cost model. The rationale was that the majority of the available cost studies 
have focused on persons with schizophrenia only and because only small differences in costs 
between different diagnoses are expected.  
 
4.10.1. Epidemiologic data review  
The best estimate for the European prevalence of psychotic disorders was 1.2% (Dominguez 
et al., 2011), of which more than half are persons with schizophrenia (prevalence of 0.635%). 
The considered age group was everyone from 18 years of age and above.  
 
4.10.2. Cost data review  
Twelve new relevant cost studies since 2004 were identified in the literature review. As stated 
in the Introduction, the majority of the studies were based on persons with schizophrenia, 
whereas three studies also included persons with other psychotic disorders. Two studies 
presented estimates from a prospective observational cohort (Garattini et al., 2004; Knapp et 
al., 2004; Mangalore and Knapp, 2007) and the third study was based on data from a clinical 
trial sample with strict inclusion criteria (Salize et al., 2009) None of these studies was 
considered for the European cost model.  
Heider at al. randomly sampled 1208 persons with schizophrenia between 18 and 64 years of 
age from patient lists in secondary care clinics (Heider et al., 2009). Persons were followed up 
to two years with assessments of their resource utilization every six months. Among the nine 
studies on persons with schizophrenia, this was preferred because it presented costs for three 
countries (France, Germany and the UK) that were estimated using a common methodology. 
This study was also preferred to the study selected in the EBC2005 study (Knapp et al., 2004), 
because it was based on a larger cohort of prospectively followed persons with schizophrenia. 
Knapp et al. recruited 404 persons with schizophrenia between 18 and 65 years of age that 
had been in contact with mental health services during the past 3 months. They then asked the 
persons about their resource utilization during the past 3 months.  
Out of the remaining eight studies, four explored the costs of schizophrenia but did not 
provide any usable estimates. One of these presented pooled data from several countries but 
no data enabling country-specific estimates, (Hong et al., 2009) another German study 
explored the effects of clinical and social characteristics on costs, and the other two studies in 
Germany and Switzerland estimated the costs of family caregivers of persons with 
schizophrenia (Lauber et al., 2005; Wilms et al., 2004). Another three studies were not 
considered for the European cost model because they used a top–down approach (Behan et 
al., 2008; Oliva-Moreno et al., 2006), or were based on a sample selected specifically for 
treatment with risperidone (Lindström et al., 2007). The study by Olivares, and colleagues 
also aimed at evaluating treatment with risperidone, but they also reported baseline costs of a 
seemingly unselected sample of persons with schizophrenia prior to the start of treatment 
(Olivares et al., 2008).  
Estimates of direct health care costs for the European cost model were selected from Olivares 
et al. and Heider et al. (Table 35).  
Neither of the two selected studies included data on indirect costs. Instead, employment data 
were collected from the European Schizophrenia cohort (Bebbington et al., 2005). They 
estimated the proportion of persons with schizophrenia that were employed at 12.9, 30.3 and 
11.5% in France, Germany and the UK respectively. The indirect costs were assumed to be 
the remaining (unemployed) proportions multiplied by the net annual income in each country, 
estimated at €24,449, €25,381, and £26,220 respectively (OECD statistics 2011 
stats.oecd.org).  
 
4.10.3. Discussion  
The latest economic evidence for schizophrenia suggests lower direct healthcare costs per 
person compared to the estimates reported in the EBC2005 study. The estimates at that time 
were all based on the study conducted by Knapp et al.(2002) who used a different 
methodology which may have resulted in higher figures. For instance, they measured the costs 
of persons that had been in contact with the health services during the same period in which 
they assessed the costs. This may have led to an overestimation because those that had not 
been in contact with health care, and therefore probably had lower costs, were omitted from 
the analysis.  
This updated review also enabled the inclusion of indirect costs which were not included in 
the EBC2005 study. The total costs per person are therefore higher in this revision. Still, the 
indirect costs were estimated based on limited data and do not include costs of potential short 
term sickleave which may have resulted in even higher estimates.  
 
4.11. Stroke  
 
Stroke is defined by the World Health Organization as “a focal (or at times global) 
neurological impairment of sudden onset, and lasting more than 24 h (or leading to death) and 
of presumed vascular origin”. Stroke may be defined as ICD 10 code I61 (intercerebral 
hemorrhage), 63 (cerebral infarction) 64 (hemorrhage or infarction) and 67 (other type). 
Transient ischemic attack (G45) is a diagnosis often excluded from the stroke, but it is a 
related diagnosis. Similar to the EBC2005 study, we do not include this in our analysis. In the 
EBC2005 study, only the costs of incident cases of stroke were considered (i.e. persons 
having a stroke in 2004). In this revision we are estimating both the costs of the incident cases 
(i.e. persons having a stroke in 2010) and the prevalent cases (i.e. persons having a stroke in 
any year prior to 2010).  
 
4.11.1. Epidemiologic data review  
A Medline search for stroke prevalence and incidence studies from Europe since 2004 was 
conducted. In comparing studies to the systematic review by Truelsen et al.(2006), this search 
yielded fairly identical results for the few countries with newer data. A standardized approach 
was taken by Truelsen et al. This has detailed prevalence and incidence data from almost all 
involved European countries, and decision was made to again use this excellent data resource.  
 
4.11.2. Cost data review  
The literature review identified 5 studies which were considered for inclusion in the 
calculations. A further study was provided via personal communication (Smith et al., 2010) as 
the authors have only recently submitted this to a peer reviewed journal. The estimates are 
taken from their corresponding national report. These estimates together, provided cost 
estimates for Germany, Ireland, Italy, Switzerland, The Netherlands and the UK, which are 
presented in Table 36.  
All of the studies concentrated on the first 12 months of costs of incident cases of stroke 
except for Gerzeli et al. (2005) that looked at first 6 months only, so we doubled this to get the 
12 months of costs for the model. The Dutch study reported direct costs for different age and 
gender groups, and an average was therefore calculated by considering the mean cost of men 
and women in those aged between 75 and 84 years of age (Struijs et al., 2006).  
Further to the 12 month data, the German and Dutch studies had a longer follow-up up to 5 
years after the stroke (Kolominsky-Rabas et al., 2006; Struijs et al., 2006). These two studies 
showed that the costs in the second year were about 25% of the costs in the first year after the 
stroke. Therefore, we assumed that the costs of prevalent cases would be 25% of the costs of 
the incident cases in each of the countries.  
 
4.11.3. Discussion  
The costs per person with a stroke within the past year (incident cases) was similar in this 
revision compared to the estimates reported from the EBC2005 study (Andlin-Sobocki et al., 
2005). Further, the same incidence data was used in both studies, resulting in the estimate of 
the number of persons increasing by the same rate as the size of the European overall 
population.  
A new contribution in this study, which dramatically increased the total estimated costs of 
stroke, is that we now included the costs of prevalent cases. These have much lower annual 
costs than the incident cases, but because they are larger in numbers they constitute a large 
proportion of the total costs.  
 
4.12. Traumatic brain injury (TBI)  
 
The EBC2005 study (Andlin-Sobocki et al., 2005) reported estimates on the acute costs of 
traumatic brain injury (TBI). The rehabilitation and long term consequences were not 
considered and little is known about their costs. Therefore, an economic model was developed 
to estimate the mean annual costs of persons suffering from a prior TBI.  
 
4.12.1. Epidemiologic data review  
The literature review identified two new studies (Cassidy et al., 2004; Rickels et al., 2010) 
confirming the incidence data suggested in the review by Tagliaferri et al.(2006). The overall 
incidence ranges between 100 and 300 per 100,000 inhabitants depending on study (Cassidy 
et al., 2004). Tagliaferri suggests 235 persons distributed over mild (186), moderate (28) and 
severe (21) TBI, per 100,000. There is limited data available on the number of persons 
suffering from a previous traumatic brain injury.  
 
4.12.2. Cost data review  
Six new studies were identified in the literature review, all presenting partial costs of TBI 
patients (Meerding et al., 2006; Morris et al., 2008; Norlund et al., 2006; Polinder et al., 2005; 
Rickels et al., 2010; Rossi et al., 2006). Two studies estimated the direct health care costs of 
all types of injuries and reported brief data on skull and brain injury at €3100 in the 
Netherlands (Meerding et al., 2006) and €2822 in 10 European countries (Polinder et al., 
2005). Another three studies estimated the hospitalization costs of mild TBI at €914 in 
Sweden (Norlund et al., 2006), isolated head TBI at €3149 in Italy (Rossi et al., 2006) and 
TBI at £15,462 in England and Wales (Morris et al., 2008). The sixth study was a population 
based study presenting data on resource use associated with headinjury in Germany (Rickels 
et al., 2010).  
The economic model was designed to estimate the number and costs of persons in acute 
trauma care, in rehabilitation or suffering from the long term consequences of a previous TBI. 
We assumed a time horizon of 20 years divided into three phases: acute (first 6 months 
following the injury), rehabilitation (the following 18 months) and finally a long term phase. 
We used different input data for each phase and severity of the TBI (mild, moderate and 
severe), including incidence rates, mortality rates, hospitalization costs, and the proportions 
and costs of patients getting rehabilitation, not being able to work, and having to live in care 
homes (Table 37).  
The number of prevalent cases in each phase and their mean costs was then calculated by 
following the path of a hypothetical cohort of incident cases over twenty years. The costs of 
all incident cases in 2010 and prevalent cases (assumed to suffer from TBI occurring between 
1991 and 2009) were calculated for each severity (Table 38).  
 
4.12.3. Discussion  
The TBI cost model provided estimates of number of persons and their annual costs per 
person, stratified by severity. These data have not previously been available. The mean direct 
health care costs (hospitalization) of the incident cases in the model (€4356) were comparable 
to the corresponding estimates in the EBC2005 study (€4143 on average), but the long term 
costs are as seen much higher.  
 
4.13. Child and adolescent disorders  
 
From the much wider spectrum of disorders with a typical onset in childhood and adolescence 
we were able to include: Autism Spectrum Disorders (ASD), Attention Deficit Hyperactivity 
Disorder (ADHD) and Conduct Disorder (CD).  
 
4.13.1. Epidemiologic data review  
As seen in Section 3.2 it was estimated that there are approx. 6 million individuals with child 
and adolescent disorders in Europe in 2010 (based on the European population aged 2–17 
years). The number of persons affected by child and adolescent disorders is for ASD based on 
a recent review study of 43 studies on pervasive developmental disorders, which indicated a 
prevalence of ASD at 0.64% (Fombonne, 2009). The boy–girl ratio was, based on the review, 
assumed to be 4:1. The number of persons with ADHD and CD is based on a prevalence rate 
that was estimated, weighted for sample size, using epidemiological studies as selected based 
on searches in Pubmed/Medline (Baumgaertel et al., 1995; Döpfner et al., 2008; Esser et al., 
1990; Ford et al., 2003; Gomez-Beneyto et al., 1994; Kroes et al., 2001; Landgren et al., 
1996; Puura et al., 1998; Steinhausen et al., 1998; Taylor and Sandberg, 1991; Verhulst et al., 
1997). The prevalence rates were estimated at 5% for ADHD and 3% for CD, respectively, 
for ages 6 to 17 and 5 to 17. Based on the reviewed studies, the boy–girl ratio for ADHD and 
CD is estimated to be 3:1. Further it was estimated that the prevalence rate decreases in 
adolescence for ADHD whereas increasing in adolescence for CD.  
 
4.13.2. Cost data review  
Regarding cost studies, literature searches identified 1732 article hits of which eleven papers 
were in the end included for final evaluation. Cost per person is highest for ASD, based on a 
UK and a Swedish study that survived exclusion criteria (Järbrink, 2007; Knapp et al., 2009). 
In the UK study, which includes ASD persons both with and without mental retardation, the 
selected cost estimate refers to persons without mental retardation.  
For ADHD a Dutch study survived exclusion criteria (Hakkaart-van et al., 2007) and for CD a 
UK study (Romeo et al., 2006). For all conditions, costs include direct and indirect costs. 
Table 39 reports the data extracted and used from the selected studies for the economic 
model. It should be noted (albeit not reported in the table) that further adjustments were made 
to account for less than 100% treatments rates (25% treatment assumed for ADHD and CD, 
which affects the direct costs).  
 
 
4.13.3. Discussion  
To note regarding child and adolescent disorders is that there is only a limited amount of 
economic studies on the cost per person in a European setting. Hence significant 
modeling/extrapolation as detailed in the Methods section has been necessary to carry out. 
Significant uncertainties include, among others, potential differences in treatment rate across 
European countries. Further, it is difficult (with precision) to estimate the excess cost to 
school services and other societal sectors apart from the medical sector that is affected 
regarding resource use as a result of persons with child and adolescent disorders.  
 
4.14. Mental retardation  
 
Mental retardation, also sometimes referred to as Intellectual Disability, refers to the ICD-10 
categories of F70–F79. It has been suggested, in revisions of ICD-codes, that the term 
Intellectual Developmental Disorder will replace Mental Retardation. However, since this is 
yet not official we will use the term Mental Retardation in this paper. Mental retardationmay 
be described as a meta-syndrome analogous to dementia, characterized by pervasive 
developmental cognitive impairment (Salvador-Carulla and Bertelli, 2008).Mental retardation 
is associated with significant health problems worldwide such as multiple disabilities and 
other medical conditions. A substantial proportion of mental retardation is due to preventable 
causes. The disease may be mild, moderate, severe or profound. The large share of individuals 
affected by this disorder has mild mental retardation (85%), whereas moderate (10%) and 
severe (4%) are profound (2%) and are less common (King et al., 2009).  
 
4.14.1. Epidemiologic data review  
As seen in Section 3.2, it was estimated that there are about 4.2 million persons with the 
disease in Europe in ages 0 to 65. This is estimated using a prevalence rate estimate of 1%, 
based on a recent meta-analysis (Maulik et al., 2011) indicating a prevalence rate of 0.92% in 
developed countries. The prevalence rate at 1%, slightly higher than the estimate for 
developed countries in Maulik et al.(2011), is motivated by the finding of higher prevalence 
rate among middleincome countries, which include a few of the European countries (Durkin, 
2002). Environmental factors such as alcoholism, lead exposure, iron deficiency,malnutrition, 
perinatal problems and many other non-genetic conditions play a major role in the excess of 
people with mental retardation in less economically developed countries (Bertelli et al., 2009). 
Studies indicate a female–male ratio varying between 0.7 and 0.9 among adults and between 
0.4 and 1 among children and adolescents (Maulik et al., 2011). In this report we assume a 
female–male ration in the midpoint of that interval at 0.8.  
 
4.14.2. Cost data review  
Regarding cost studies, literature searches identified 817 hits of which ten papers were 
included for final evaluation. Most papers were based on very specific disease samples in the 
UK, indicating a great need for additional COI studies on mental retardation. One study 
surviving basic exclusion criteria is a Dutch study using a top–down approach with a health-
care perspective (Polder et al., 2002). Below the data from the study that was used as inputs in 
the economic model, are presented (Table 40).  
 
4.14.3. Discussion  
The annual cost per subject with mental retardation used in the economic model is a 
conservative estimate of the economic cost of the disease since it does not include most of 
direct non-medical costs due to the disease, such as the extra resources needed in educational 
and social service sectors. Neither does it include indirect costs in terms of lost productivity. 
Considering that it is known that employment is very low among individuals with MR, 
including indirect costs would have implied a significantly higher cost per person (Martinez-
Leal et al., 2011).  
 
4.15. Eating disorders  
 
It was estimated that about 1.5 million persons in Europe are affected by Eating Disorders, 
which here includes Anorexia Nervosa and Bulimia Nervosa (category F50.0 and F50.2 in 
ICD-10, respectively). Other conditions, such as Binge Eating Disorder, are not included in 
this report and would have, obviously, implied a larger number of persons affected.  
 
4.15.1. Epidemiologic data review  
The number of persons estimated with Eating Disorders is based on a prevalence rate of 
0.54% for Anorexia Nervosa and 0.86% for Bulimia Nervosa in the age range 14 to 17 years. 
For the adult population, 18–65 years, a lower prevalence rate at 0.21% for Anorexia Nervosa 
and 0.14% for Bulimia Nervosa was assumed (Jacobi et al., 2004).  
 
4.15.2. Cost data review  
Regarding cost studies on Eating Disorders, the literature searches identified 237 hits, of 
which only four papers were considered for inclusion. Of these four papers, only one paper 
actually contained enough data in order to be useful (and passing exclusion criteria) (Krauth 
et al., 2002).  
The study contains cost per person data for Anorexia Nervosa and Bulimia Nervosa and is 
based on a German sample with a bottom–up methodology. Cost estimates are based on 
benefit data from health and pension insurance schemes. In the report we exclude costs due to 
premature mortality from the study, and therefore the data on cost per person used here is 
lower compared to what is reported in the included study (Krauth et al., 2002).  
Below is the data that was used as inputs in the economic model. Excluding prematurely 
mortality costs, cost per person for Anorexia Nervosa is €1984 and €117 for Bulimia Nervosa. 
It should also be noted that an assumption of a treatment rate below 100% is included in the 
cost modeling; with a treatment rate of 50% for Anorexia Nervosa and 25% for Bulimia 
Nervosa (direct costs were reduced accordingly) (Table 41).  
 
4.15.3. Discussion  
There are several reasons to believe that these are lower limits of the true cost per person with 
Anorexia and Bulimia Nervosa. Several resource items are missing from the study, including 
most outpatient resource use and informal care costs; e.g. lost productivity among parents or 
caretakers resulting from the disorder among adolescent persons.  
 
4.16. Personality disorders  
 
Personality Disorders (PD) included in this study only take into consideration the cluster B 
disorders (Borderline Personality Disorder and Antisocial Personality Disorder) as no solid 
estimates could be obtained for other personality disorders. These refer to categories F60.31 
and F60.2 in ICD-10, respectively. Based on the age range between 18 and 65 years it was 
estimated that 4.4 million persons in Europe are affected by these two personality disorders.  
 
4.16.1. Epidemiologic data review  
The number of persons affected by personality disorders is based on a prevalence rate of 0.7% 
for Borderline Personality Disorder and 0.6% for Antisocial Personality Disorder in the age 
range 18 to 65 (Coid et al., 2006). There is also a significant age profile for personality 
disorders, with higher prevalence in young adulthood as compared to later in life; with an age 
ratio of among 10:1 for Antisocial Personality Disorder and 8:1 for Borderline Personality 
Disorder in the age range 18–29 in relation to the age-range 45–65. 4.16.2. Cost data review 
Regarding studies on the cost per person of personality disorders, literature searches identified 
941 hits. In the end eleven papers were considered for inclusion in the project. After full 
evaluations a cost per person for Antisocial PD is based on a Dutch study including both 
direct and indirect costs (Soeteman et al., 2008). Cost per case for Borderline PD is also based 
on a Dutch study including both types of costs (van Asselt et al., 2007). Both studies are 
based on a bottom–up approach.  
Below is the data from the study that was used as inputs in the economic model. It should also 
be noted that an assumption of a treatment rate below 100% is included in the cost modeling; 
with a treatment rate of 30% for Borderline PD and 10% for Antisocial PD (direct costs were 
reduced accordingly) (Table 42).  
 
4.16.3. Discussion  
Cost per person is higher for Borderline PD with an estimated cost per treated person at 
€16,205 per year. The largest cost component is indirect costs, mainly caused by productivity 
losses due to disability and to some extent due to higher absence from work. The quite 
significant direct non-medical costs mainly contain informal care costs. For Antisocial PD a 
higher share of costs are due to direct health care costs. It should also be mentioned that the 
cost per person does not include e.g. crime costs that may be significant for persons with 
Antisocial Personality Disorder.  
 
4.17. Sleep disorders  
 
It was estimated that there are approx. 45 million persons affected by sleep disorders in 
Europe in 2010. This was based on the inclusion of the following specific diseases in the 
category of sleep disorders: Sleep Apnea, Insomnia, Narcolepsy and Hypersomnia.  
 
4.17.1. Epidemiologic data review  
Assumed prevalence rates are seen in Table 43. The highest prevalence rate is seen for 
Insomnia, followed by Sleep Apnea, Hypersomnia and Narcolepsy.  
 
4.17.2. Cost data review  
Regarding cost data for sleep disorders 1067 hits were identified in the first round of searches, 
and in the end six papers were considered of which five are included in the model. Cost per 
person of insomnia is based on two French studies in order to gather both direct and indirect 
cost data (Godet-Cayré et al., 2006; Leger et al., 1999). Cost per case for Hypersomnia, 
Narcolepsy and Sleep Apnea is based on three different studies using Danish register data 
with a common methodology, retrospective bottom–up studies, including both direct and 
indirect costs (Jennum et al., 2009; Jennum and Kjellberg, 2010, 2011) (Table 44).  
 
4.17.3. Discussion  
Narcolepsy is the condition among sleep disorders with the highest cost per person, mostly 
explained by high indirect costs due to lower employment (matched to control group) among 
individuals with narcolepsy as well as lower income if employed.  
 
4.18. Neuromuscular disorders  
 
Neuromuscular disorders cover a wide range of different conditions with varying causes and 
consequences. In the project it was initially decided to divide Neuromuscular Disorders into 
five different categories, but a lack of economic cost data implied that we had to narrow the 
number of included conditions. And as described in Section 3.2, included Neuromuscular 
Disorders in the study are categorized as:  
 
(1) Muscular Dystrophies (MD) and other genetic myopathies: Duchenne, Becker, 
Facioscapulohumeral (FSHD), Limb Girdle, Emery–Dreifuss MD (EPMD), Oculopharyngeal 
MD (OPMD), Congenital MDs, Congenital myopathies, Distal and Myofibrillar Myopathies 
and Myotonic dystrophies,  
 
(2) Acquired Neuropathies: Chronic Inflammatory Demyelinating Polyradiculoneuroapthy 
(CIDP), Multifocal Motor Neuropathy (MMN), Paraproteinemic Polyneuropathies (PDN), 
Guillain–Barré Syndrome (GBS) and Amyotrophic Lateral Sclerosis (ALS),  
 
(3) Autoimmune Disorders of muscle and of the neuromuscular junction: only possible to 
include Myasthenia Gravis.  
 
4.18.1. Epidemiologic data review  
Most neuromuscular disorders are rare and it was estimated that the number of persons with 
any one of the conditions listed above is about 0.25 million in Europe. This is based on 
prevalence rates as described in Table 45.  
Note that the number of persons estimated to be affected with Neuromuscular Disorders lacks 
a number of important conditions such as Hereditary Neuropathies (e.g. Charcot– Marie 
Tooth disease), Spinal Muscular Atrophies, Inflammatory Myopathies (Dermatomyositis, 
Polymyositis, and Inclusion Body Myositis, Glycogen Storage Diseases, Mitochondrial 
Cytopathies) and several other conditions. Including these conditions would obviously have 
increased the number of persons estimated to be affected with Neuromuscular Disorders.  
 
4.18.2. Cost data review  
Regarding cost studies, literature searches of NMD gave 829 hits, and in the end 4 papers 
were considered for inclusion in the model. For NMD an exception regarding exclusion 
criteria for countries was made; an Australian study is used in order to estimate cost per case 
for muscular dystrophies (AccessEconomics, 2007). Other included studies are based on 
samples in Germany, France and the UK (Espèrou et al., 2000; Mahdi-Rogers et al., 2008a,b, 
2009; Schepelmann et al., 2010). Shown in Table 46 is the data from the studies that were 
used as cost inputs for the model.  
 
4.18.3. Discussion  
The cost per persons with Neuromuscular Disorders is relatively high. It should also be 
mentioned that some of the excluded conditions (due to lack of relevant economic studies) are 
thought to be very costly, such as acid maltase deficiency (the cost of enzyme replacement 
therapy is extremely high), and would have implied a significantly higher economic burden 
due to Neuromuscular Disorders.  
 
4.19. Somatoform disorders  
 
Somatoform disorders describe a heterogenous group of mental disorders ranging from 
hypochondriasis over pain to somatization disorder. The descriptive hallmark of these 
disorders is the patients' cognitive distortion regarding physical symptoms and their illness 
behavior. Such patients perceive obviously normal physical sensations of their body functions 
as being proof of having illness and consequently persistently seek medical advice and 
treatment because of perceived physical symptoms for which treating physicians could not 
find a reasonable explanation. Depending on the type and form of patients' symptoms, 
different sets of diagnostic criteria have been established. The economic burden of 
somatoform disorder is typically considered to be extremely high, because by diagnostic 
definition theses disorders have to be associated with high, medically not justified doctor 
visits and numerous and sometimes even invasive medical investigations, consultations and 
testing of various treatments. Distress and suffering of such patients are typically high, and 
patients also commonly unable to work resulting in extensive sick leave and early retirement.  
 
4.19.1. Epidemiologic data review  
A review of European studies suggested a median European prevalence of 6.6%. For our 
study, to avoid overlap with headache dealt with separately, we estimated the proportion of 
subjects with somatoform disorders exclusively due to headache and excluded such patients, 
resulting in an adjusted prevalence of 4.9% (Wittchen et al., 2011). The available evidence 
suggests that this prevalence is applicable to persons from 18 years and above, but only those 
between 18 and 65 were considered for the cost calculations.  
 
4.19.2. Cost data review  
The most recent study that estimated the costs of persons with non-psychotic disorders was 
recruited from a Dutch population based cohort (NEMESIS) (Cuijpers et al., 2010). However, 
estimates were only presented by subgroups based on the individual scores on a neuroticism 
scale, and no reliable estimate of the cost of a person with somatoform disorder could 
therefore be derived from this study. Reid et al. (2002) studied a selected sample of what the 
authors call “frequent attendees” in secondary care without using specific criteria for 
somatoform, disorders. examined consecutive patients registered for inpatient treatment at a 
behavioral medicine clinic in Germany, reporting direct health care costs and sick-leave days 
and also considered various subgroups (Hiller and Fichter, 2004).  
The lack of diagnostically and clinically meaningful sound cost data that could be translated 
in a reasonable way to our reference population of patients, thus prohibits use of these study 
data. In order to at least have a conservative proxy for this important groups of patients we 
decided to use the German community based study (GHS–MHS, (Jacobi et al., 2002)) which 
also assessed the resource use of persons with somatoform disorder. The excess costs of each 
person were estimated by multiplying the difference between those meeting the diagnostic 
criteria for one somatoform disorders included versus those not meeting these diagnostic 
criteria, taking into account unit costs of each resource. Resources included visits to primary 
care and specialists, inpatient stays and indirect costs due to absence from work (potential 
indirect costs of those outside the workforce were not considered). Direct healthcare costs 
were estimated at €720 per person and indirect costs at €899 (both in 2004 values). These 
estimates were used in the European cost model.  
 
4.19.3. Discussion  
It should be noted that the presented estimate for somatoform disorder is conservative, due to 
the exclusion of headache. The prevalence in the GHS–MHS (Jacobi et al., 2002) study was 
11% which indicates that they included a broader range of persons.  
 
 
5. Discussion  
 
5.1. Main findings  
 
This study provides the currently best possible estimates of the cost of disorders of the brain 
in Europe in the year 2010, based on the latest available evidence. In comparison to our 
previous 2005 estimate based on a more restricted set of diagnoses as well as a smaller 
European reference population, we showed that the estimate presented in the EBC2005 study 
remains quite stable if correcting for inflation and the increase in the population. The 2004 
estimate of €386 billion translates into €488 billion given the current 2010 price levels and 
population size, which is comparable to our revised estimate for the same disorders of €477 
billion in 2010.  
 
Our 2010 revised estimates for exactly the same twelve diagnostic groups covered in the 2005 
report also confirmed our previous interpretation and conclusion that our estimates would be 
even higher if all costs of these disorders were considered. In the present study, important 
elements were added that were lacking in the EBC2005 study due to a lack of data. These 
“elements” included new sub-diagnoses such as non-migrainous headaches and post traumatic 
stress disorder, the long-term costs of persons having a stroke or traumatic brain injury in 
previous years, and the indirect cost of psychotic disorders and traumatic brain injury. 
Incorporating these dimensions added another €164 billion to the cost of the originally 
included 12 disorders.  
 
In the present study we also estimate the cost of an additional seven important groups of 
disorders of the brain. They were not considered at all in the EBC2005 report due to lack of 
data. The total cost of these disorders amounted to an additional €157 billion.  
 
In total we come to the conclusion in our current report that the cost of disorders of the brain 
amounts overall to a staggering €798 billion in Europe in 2010 or more than the double of our 
previous estimate.  
 
Lots of somewhat less prevalent disorders are, however, still missing in the present report due 
to lack of data. The “true” estimate of the cost of disorders of the brain is therefore probably 
considerably higher. More research, particularly of cost items, is needed on all disorders of 
the brain.  
 
5.2. Possibilities for over- and underestimations  
 
The biggest risk of overestimation of cost in our study is the possibility of double counting 
discussed throughout in our report. The best way to avoid this risk would have been to do 
field studies in all European countries of representative samples from the general population, 
covering the full spectrum of disorders of the brain in one study. We have previously made 
plans for such a study but found that even with a number of simplifications and compromises, 
such a study of 19 groups of disorders of the brain in 30 countries would cost in excess of 
€100 million and would thus be unrealistic. We believe – as discussed below – that we have 
been able to largely eliminate double counting in the present study.  
 
While overestimation is a theoretical possibility, there are many underestimations that are 
certain. First, many cost items are still not included in our study including indirect cost of 
insomnia, mild traumatic brain injury, mental retardation and child and adolescent disorders. 
Second, for some disorders only a limited age group has been evaluated, for example the 
estimated huge cost of adults with autism was not included due to limited data and all pain 
related somatoform disorders were also not included. Third, many neuromuscular disorders, 
rare genetic disorders, dystonia and several other neurological diseases have not been 
included at all. The same is true of a multitude of less common psychiatric disorders, in fact 
many more than have been included albeit more rare disorders. The consequences of tobacco 
addiction and crime due to addiction to opiates are very costly, but they are not included. 
Additionally, appetite regulation is a neurobiological phenomenon but obesity has not been 
included under eating disorders.  
 
Fourth, the cost of crime in alcohol dependence was estimated at around €1500 (PPP 2010) 
per person in Estonia and Sweden (Jarl et al., 2008; Saar, 2009). Extrapolated to the whole of 
Europe this amounts to 24 billion in total costs. Estimates for opioid dependence showed 
larger variation; €1200 in Spain, €9140 in France and €61,321 in the UK, which amounts to 
14 billion in total costs if extrapolated to Europe.  
 
Fifth, the evidence of premature mortality is available for some disorders but not for others. In 
brain tumor, the cost of premature mortality constitutes about 5.3 billion. Estimates were also 
available for substance use disorders but were not included in the main results. The available 
data from Estonia, Germany, Sweden, France and Spain suggest costs in the range of €4200 to 
€5200 for alcohol dependence and about €1300 for opioid dependence. This amounts to €58 
billion in total costs for Europe for alcohol dependence and €1.5 billion for opioid 
dependence. The cost of premature mortality could be studied using a comparatively simple 
but consistent method across all disorders, by analysis of registry data on mortality. Such data 
are available in Sweden and Denmark, including the cause of death by ICD-10 codes. An 
important advantage of such analysis would be that double counting could easily be avoided 
by only considering one diagnosis per person, i.e. the main diagnosis according to the registry 
data.  
 
Sixth, the cost of cannabis dependence could not be included in this review because of lack of 
European data. However, evidence from the US suggests that the treatment cost alone can be 
substantial, estimated at between $837 and $3334 per patient (1999 USD). Assuming the 
same cost in Europe and that half of all 1.4 million persons with cannabis dependence in 
Europe would get this treatment would result in figures in the range of €0.5 to €2.5 billion 
(PPP 2010).  
 
In conclusion there is no doubt that the estimates presented in this report of the cost of 
disorders of the brain in Europe in 2010 are very conservative. They probably represent an 
underestimation although they are more realistic and complete than the data we published in 
2005.  
 
5.3. Strengths and limitations of the methodological approach  
 
The estimates presented in this report are based on model extrapolations of previously 
published data on the prevalence and cost per person of each disorder. There are several 
advantages of this approach. First, it enables consideration of all of the available evidence 
even if different methods are used for different studies and only partial information is 
presented in each single study. Thereby, the combined knowledge and experience from the 
entire research community contributes to make the estimates as accurate as possible. Second, 
wherever data are not available, estimates can still be produced by imputations from the 
available evidence, for example from another country or group of similar persons. Not only 
does this enable estimates in countries and subgroups where no primary data are available, but 
it also enables aggregated estimates for all disorders of the brain in the whole of Europe. 
Third, adjustment for inflation, exchange rates and purchasing power parities allows for 
combining studies reporting estimates for different years, currencies and countries which 
further increases the evidence base supporting the final estimates. An alternative approach 
may be to collect primary data with a common protocol for all disorders of the brain and in all 
countries of Europe. This would be a very interesting study, albeit extremely ambitious and 
costly if seriously undertaken.  
 
In order to arrive at comparable estimates for each disorder, a consistent methodology was 
specified for all disorders of the brain. Small differences were allowed (e.g. in the selection of 
input data from the identified studies and assumptions for the modeling) as specified in the 
disorder specific sections, to accommodate differences in the data availability and the care 
patterns for different disorders. At the same time being an important condition for relevant 
estimates in the context of this study, the common methodology employed for all disorders 
may explain differences in our estimates to other studies focusing on each disorder separately. 
It may very well be the case that a different methodological approach would be more 
appropriate for a study focusing on a single brain disorder.  
 
As estimates were not available for many countries, we imputed the prevalence and cost for 
these from countries with available data. The methods selected for imputation aimed to be 
specific enough to give accurate imputations taking known differences across countries into 
account, while also being straightforward enough to avoid debatable assumptions that may be 
contested depending on the perspective of the reader. For this reason we decided to consider 
the median estimates of both prevalence and costs and only make adjustments for the different 
price and income levels of in each country. Thereby we opted not to consider different regions 
of Europe which are complex to define and seemingly impossible to defend within the context 
of the European Union. Further, the median was preferred to the mean because it avoids the 
influence of outliers that might have skewed the results.  
 
5.4. Input data  
 
The accuracy of model estimations is always dependent on the input data. The main inputs 
into our model were the estimated number of persons affected by the disorders, the costs per 
person, and country specific indices and demographics. Country specific indices and 
demographics are readily available from Eurostat and should be considered valid for all 
European countries without further commenting. By contrast, the prevalence and cost data are 
uncertain and may be discussed further.  
 
The prevalence estimates should be considered as being relatively robust overall. Most 
estimates are based on well designed population based surveys reporting estimates that have 
been scrutinized and confirmed in several studies and countries. However, evidence for all 
countries was not available for any of the disorders, which implies that assumptions have to 
be made about the prevalence in one country based on data from others. We assumed the 
European median prevalence for each disorder in all countries where no data were available. 
This is a valid approach as long as there are no important differences in prevalence across 
countries or regions in Europe. This is likely not the case for alcohol addiction which was also 
the rationale for making an exception for this diagnosis by considering regional prevalence 
estimates.  
 
Estimates of the cost per person may be considered less robust across studies and countries in 
comparison to the prevalence estimates. Most cost studies are based on clinical samples of 
persons and their cost may not be representative to the overall patient population. We adjusted 
for this whenever considered appropriate by multiplying the cost estimates by a factor 
reflecting the proportion of persons that could be assumed to incur the estimated cost. 
Moreover, it is difficult to get an accurate representation of the severity of persons in a 
clinical sample. It may for instance be easier to recruit less severe persons which are able to 
respond to questionnaires themselves than the more severe persons who may need a caregiver 
to assist them. One way of addressing this issue is by estimating the cost by categories of 
severity and combine with similarly defined prevalence estimates by severity. This approach 
was considered for the present study but the available data are still too scarce in most 
disorders, though with some exceptions including dementia and multiple sclerosis.  
 
There is a lot of variation in the designs of the identified cost studies. Most are bottom–up 
which was preferred in this review because of the reasons given in the Methods section. 
However, in some disorders (e.g. substance use disorders) we had to rely on top–down studies 
in absence of other data. In such studies, the relevant estimate is the total cost reported for a 
country which means that the cost per person is given by dividing the reported cost by our 
estimate of the number of persons, rather than the number of persons potentially reported in 
the cost study. Otherwise, the total cost may get to something else in the end. Another 
common discrepancy of the cost studies is related to which costs were actually included in 
their estimates. We extracted separate estimates for direct healthcare, direct non-medical and 
indirect costs. Whenever possible we adjusted the estimates for types of costs that given our 
definitions should not be included in each of the three categories. For instance, informal care 
is commonly considered an indirect cost whereas in our study we consider it a direct non-
medical cost. Still, in many studies the data may not be detailed enough for either categorizing 
into the three types or in some cases even determine exactly what types of costs were included 
at all. The estimates may therefore vary because different resources are included in different 
studies.  
 
5.5. Co-morbidities  
 
As commented in the Results section on aggregated costs, there is considerable overlap 
between the disorders of the brain. This problem is even larger in this revision compared to 
what was reported in the EBC2005 study, simply because we have now considered seven 
more groups of disorders. The magnitude of this problem should be considered lower for 
disorders that are very costly but affect small numbers (e.g. MS and brain tumor), while the 
consequences of double counting may be larger for disorders that affect larger numbers. The 
aggregated number of persons should not be interpreted as the actual number of Europeans 
with a brain disorder, because some have several disorders adding to the aggregated figures. 
Similarly, there is risk of double counting in costs if the cost of the same person with two 
disorders is counted twice. To the extent possible, we included only the excess cost of each 
particular disorder but because of variation in the design of the cost studies and limitation in 
the available data,we have probably not corrected for all overlap across disorders.  
 
5.6. Policy implications for research, patient care, education and drug development  
 
5.6.1. Research with a European focus  
For many years, epidemiological studies done in one or a few places in the United States have 
been taken to represent the whole of the United States of America. Cost studies have been 
generalized in a similar way. These studies have sometimes taken into account different 
demographics and socioeconomic characteristics of the different states but most often not. In 
Europe there has not been a tradition to generalize results obtained in individual national 
states to all of Europe. To a large extent, the necessary methodology for imputing values for 
all of Europe has not been in place. Our first study of the Cost of Disorders of the Brain in 
Europe published in 2005 was in this respect pioneering. Just to estimate the cost of a single 
disorder in all of Europe including values for every single country had not been done before. 
Nevertheless, this was achieved for 12 major brain disorders for which data were available at 
the time.  
Considerable methodological development was thus part of our first study. More than a 
hundred experts in epidemiology collaborated with a large group of health economists in 
order to jointly develop the best possible estimates of prevalence and cost of disorders of the 
brain. Despite all difficulties this collaboration worked extremely well and the first cost study 
was produced in only two years.  
Due to its pioneering nature and the relative lack of data, the first cost study was of course far 
from perfect. To overcome the difficulties, it proved extremely important to have a close 
collaboration between epidemiologists and health economists. In the present study we have 
used exactly the same methodology, again employing almost a hundred epidemiologists 
throughout Europe and many expert health economists. Again the work has been done in less 
than two years and we can now present much improved estimates, as discussed elsewhere in 
the present report.  
 
5.6.2. Policy implications for European research  
Data from the WHO have suggested that brain disorders account for 35% of the burden of all 
diseases in Europe (Olesen and Leonardi, 2003). Subsequently a more detailed study has 
shown that neurological disorders account for approximately 12% of the burden of all 
diseases in Europe (Neurological disorders, public health challenges, WHO, 2006). These 
figures are quite plausible against the background of our present results, demonstrating that 
disorders of the brain account for 25% of the direct healthcare costs in Europe and that 
indirect costs add considerably to this figure.  
The huge cost of disorders of the brain indicates of course that brain research should receive a 
considerable proportion of healthcare research funding, particularly in light of severe 
deficiencies in available effective treatments and poor service provision as described earlier 
(Wittchen et al. 2011). In a previous paper entitled “Resource allocation to brain research in 
Europe (Sobocki et al., 2006)” we argued that brain research is not funded sufficiently in 
relation to the huge cost burden associated with disorders of the brain. Now, with the much 
improved and consolidated cost estimate one might argue even more forcefully toward 
increased research spending, in order to cope with immense problem constituted by disorders 
of the brain. It was calculated that the return on investment in brain research far exceeded the 
return from any other branches of research when looking at the total societal prospective. That 
statement is also reinforced by the present much higher expenses.  
Undoubtedly, there have been significant improvements in the funding of brain research at the 
European Commission level. Unfortunately, this improvement started from a very low level 
of €85 million spent in the fifth framework program (FP5). In FP6 this figure improved to 
€260 million and during the first three calls of FP7, €381 million has been spent (European 
Commission, 2009; Framework Programme 6 2009 
http://ec.europa.eu/research/health/medical-research/pdf/ brain-research-eu-funding-2002-
2009_en.pdf). Still, these figures constitute only 0.05% of the estimated cost of brain 
disorders in Europe in 2010. However, in the FP7 2012 Health Programme, a total of €684 
million will be allocated, none of which will be specifically allocated to disorders of the brain. 
It therefore remains to be seen if the percentage allocation of funds to brain research is going 
to change at all in FP7 despite the specific mention of brain research in the program text. 
Europe 2020 has a Flagship initiative the Innovative Union to drive this agenda forward. Our 
data strongly support a focus on brain research in this program and throughout the EU.  
Presently, plans are under discussion for FP8. With the new cost data at hand, it is clear that 
brain research must maintain its current visibility and in fact should receive even more 
attention than currently. Likewise, our data suggest that national research programs 
throughout Europe should give considerably increased attention to brain research.  
 
5.6.3. Policy implications for European health care  
In the health care policy of the European Commission, brain disorders have already received 
some attention. It has primarily been manifest in the European Pact for Mental health, a very 
important initiative. Unfortunately, the European Commission has adopted WHO terminology 
in which mental health partly includes neurological disorders. Further, it should be 
highlighted that the term mental health has little to do with mental disorders, because it 
encompasses a much wider non-clinical perspective addressing well-being and social security 
issues.  
What is clearly required now is a coordinated policy covering all disorders of the brain, 
mental and neurological disorders alike, because together they constitute by far the biggest 
health problem in the European Union. Furthermore, we have to emphasize that the burden of 
disorders of the brain will likely increase further, simply due to the continuing trend of 
increasing life expectancy in Europe. Because of the aging European population, degenerative 
disorders are particularly destined to become more common, such as dementia, Parkinson's 
disease and stroke, but anxiety and mood disorders are also very prevalent at high age. An 
increased life expectancy also means for almost all disorders more years spent with the 
disorder and the associated disability. Thus, disorders of the brain are the core challenge of 
the future and we must start to address this issue as early and forcefully as possible.  
While increased basic research into the causes of disorders of the brain and their improved 
treatment is of paramount importance, increased focus on the prevention of disorders of the 
brain is a particularly important high priority goal, ultimately bound to improved etiological 
knowledge about diseases. Options to address the problem are evident, ranging from 
increased resources for treatment to developing “best practice models” in the organization of 
health care systems for the different brain disorders. A positive example is the organization of 
acute stroke care in specialized units. In several European countries this has been done at zero 
extra cost to the health care system because of shorter admissions. The gains have been to 
reduce long term disability, nursing home placements and death. Centralization of dementia 
care in specialized units where a neurologists, psychiatrists and geriatricians collaborate is 
also increasingly recognized to be effective and health care programs for the major psychiatric 
disorders likewise. It is however, a huge task to gradually get best practice implemented in all 
European countries.  
 
5.6.4. Policy implication for European health educations  
In most European countries the curricula at medical schools and other health care educational 
institutions reflect clinical concepts about disorders of the brain that are clearly outdated and 
not in agreement with our current state of knowledge. In the past, most disorders of the brain 
were ill-defined, with few scientifically sound and empirically based treatments available. 
Today, the situation is radically different. No field of medicine and the health sciences has 
experienced greater advances than psychiatry, neurology and the allied disciplines of clinical 
psychology and psychotherapy. Previously untreatable patients with diagnoses that bound 
them to long-term or even lifelong institutionalization in the past, can now live with no or 
minimal disability in the community and participate fully in society. Drug and psychological 
treatments have during the past two decades become available that enabled the closing of over 
half of all costly psychiatric hospital beds, and mental disorders are now managed through 
outpatient strategies. Treatments are also available for all the major neurological disorders, 
allowing to improve functioning, delay progression or even fully rehabilitate patients 
improving quality of life greatly.  
Our EBC “size and burden” (Wittchen et al. 2011) and the present EBC “cost” report 2011 
highlight that disorders of the brain are the core health challenge of the future. Radical 
revisions to school curricula in medicine and other health professions are needed to properly 
inform all health professions about the fact that over 1/3 of the total EU population is or has 
been affected by disorders of the brain, and many more will additionally suffer from such 
disorders in their future. Such messages, along with improved science-based curricula about 
the brain and its different types of disorders, must be communicated widely and translated to 
immediate action.  
In most medical schools the clinical part of the study lasts at least two years. Out of these 24 
months it is unusual to spend more than two months or 8% of the time in neurological and 
psychiatric departments. Similarly, neurophysiology, neuroanatomy, neuropharmacology and 
neurochemistry constitute only a small fraction of the preclinical curriculum. It is, however, 
no longer unreasonable to demand that 1/3 of the curriculum at these institutions should focus 
on the brain and its disorders. This pertains to basic disciplines such as physiology, 
biochemistry and anatomy as well as to the clinical disciplines. The situation is probably 
worse, not better, in other health profession curricula. During the Year of the Brain 1997 in 
Denmark, we discovered that the theoretical part of the education of nurses contained next to 
nothing about brain anatomy and physiology. Clinical education within neurology and 
psychiatry was optional. In order to improve the situation and bring it in accordance with the 
huge cost of brain disorders, European wide studies of brain related curricula of all kinds of 
health care educations should be performed.  
 
5.6.5. Policy implications for the European pharmaceutical industry  
Brain disorders are usually chronic, and the most burdensome brain disorders are caused by 
disturbances in brain chemistry, not brain anatomy. This means that the disorders, in theory, 
should be completely reversible if sufficiently specific and effective drugs or respectively 
specific behavioral treatments were available. At the time of the first cost study, the socalled 
central nervous system (CNS) indications, another word for brain disorder indications, was 
still a favored topic in the pharmaceutical industry. This has changed for the worse, despite 
the growing societal and cost burden of disorders of the brain demonstrated here. There are 
two important and potentially disastrous reasons for this. One is that the pharmaceutical 
industry in general is moving out of Europe, primarily to the United States but also to China, 
India and other places. The other reason is that industry in general has been disappointed by 
its investments in medicines for brain disorders. Both these unfortunate developments also 
have political reasons and can be potentially remediated by political means. The industry 
ismoving out of Europe for administrative and economic reasons such as the lack of a single 
European patent, time consuming and expensive recognition procedures in the different 
countries and time consuming and expensive reimbursement negotiations in each single 
country in Europe. In comparison, the United States has only one recognition, that of the 
FDA. More serious is the movement away from research in brain disorders. To a large extent 
this is also politically determined because of stricter regulations for drugs with an effect on 
the central nervous system. Political action could for example include simplification of 
procedures, reducing bureaucracy or perhaps prolonging patents for drugs for brain diseases. 
As more companies move away from research into brain disorders this will also reduce 
funding through the Innovative Medicines Initiative (IMI), a public–private partnership 
between the European Commission and the European Federation of Pharmaceutical Industries 
and Associations (EFPIA) as brain disorders are less likely to be chosen.  
The increasing burden and the associated increasing cost of disorders of the brain is a ticking 
bomb under the European economy and the EU society as a whole. There are possibilities to 
improve prevention, but a real change in the outlook is only likely to come from the 
development of new, more specific and effective drugs and non-drug treatments as well as 
improved treatment resources. For example, currently the expense for drugs acting on brain 
disorders is only 16% of the total drug consumption in Europe and thus far below the 35% of 
cost incurred by these disorders. Furthermore, the cost of drugs for brain disorders constitutes 
only a very small fraction of the total cost of these disorders.  
 
 
6. Conclusion and recommendation for political action  
 
In the 27 EU countries plus Norway, Iceland and Switzerland with a population of 514 
million people, we have estimated that cost of disorders of the brain is €798 billion per year. 
This cost burden corresponds to 25% of the direct health care expenses and the non-medical 
direct cost as well as the indirect costs, such as lost work time, are higher than for most other 
diseases due to the persisting nature of many brain diseases. In total, probably one third of all 
health related expenses are caused by brain disorders.  
 
This huge cost burden corresponds well to WHO estimates that the burden in non-economic 
terms of brain disorders is approximately 1/3 of the burden of all diseases in high income 
countries.  
 
On the basis of these figures which are as high as or higher than for heart diseases, cancer and 
diabetes combined, we have the following recommendations for political action.  
 
1. The European Commission and national governments should make disorders of the brain a 
high priority topic, and should maintain and further strengthen existing program initiatives in 
this field.  
 
2. The current focus on mental health of the European Commission should be expanded to 
include all brain disorders.  
 
3. Core emphasis should be laid on research into the causes and developmental pathways of 
disorders of the brain and their relationship in order to develop improved drug and 
psychological treatments as well as to allow for empirically based prevention.  
 
4. The European Commission should consider the state of curricula and training in all health 
professions regarding coverage of disorders of the brain. Current curricula and training appear 
to be inappropriate and outdated, neglecting in some places entirely the size and burden of 
disorders of the brain.  
 
5. The European Commission should take all necessary steps to encourage industry and 
investors to engage in brain research in order to relieve the core health challenge of the future.  
 
6. The momentum and expertise from the present effort on the size, burden and cost or 
disorders of the brain should be maintained by funding and supporting all initiatives aiming to 
provide further improved knowledge of the prevalence and cost of brain disorders in Europe.  
 
7. National policies in each state of Europe should adopt and respectively modify these 
agenda points according to the specific situation in their country in order to promote the 
health of their citizens and to contain the immense and expanding cost of disorders of the 
brain.  
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